Stock Finder

Rev +59% / EPS +109% YoY, ROE 22.5%, net debt 0.4x EBITDA, fwd P/E 10.2 and 5.7% FCF yield; premier short-cycle Delaware/Utica leverage to the Brent >$100 shock (Energy XLE O/O/O, Oil SO short) but only +8.6% to the US$159.85 mean target.

Rev +46% / EPS +242%, ROE 19.3%, FCF C$9.2bn = 8.3% yield at a 32% payout, net debt ~0.7x EBITDA; integrated oil-sands + record refinery utilisation is the cleanest Canadian expression of Energy O/O/O, though at 99% of its 52-wk high only +9.9% to the C$104.75 mean target.

C$70.86 (52-wk 41.67-72.29), ROE 26.7%, rev +69.5% / EPS +84%, net debt ~0.9x EBITDA, FCF C$7.4bn at a 43% payout, 25 consecutive dividend raises; long-life low-decline oil sands is the highest-quality Canadian barrel under Energy O/O/O - but at 98% of its 52-wk high the C$71.95 mean target is only +1.5% away. The NYSE line (CNQ) is the same issuer and is merged into this Canadian listing.

ROE 20.9%, rev +42% / EPS +239%, FCF C$5.5bn = 6.5% yield at a 23% payout, net debt ~0.8x EBITDA; Strong-Buy consensus (1.44) and +9.7% to the C$50.44 target. Integrated upstream+downstream captures both the crude spike and the crack, fitting Energy O/O/O; MEG integration is the execution risk.

Rev +52.5%, fwd P/E 11.1 vs a trailing 38.3 distorted by impairment, FCF $5.0bn = 8.9% yield, net debt ~1.3x EBITDA; lowest-cost pure Permian short-cycle barrel with +15.5% to the $232.54 mean target - the best oil-price torque in the US Core lane under Oil SO/O/U.

Peer-lane add off EOG; fills the mid-cap E&P roster gap. Rev +27% / EPS +161%, fwd P/E 7.0 and PEG 0.71 - the cheapest E&P in the section - 49% operating margins, founder-led (Joe Foran) with high insider ownership, Strong-Buy 1.45 and +12.7% to target. Net debt ~1.65x EBITDA and FCF -$0.9bn while Delaware development and San Mateo midstream are funded. Pure short-cycle oil torque for Oil SO(short).

Fills the US natural-gas E&P roster gap. Largest US gas producer, net debt ~0.7x EBITDA, 11.1x forward / P/B 1.17, FCF $1.47bn = 6.3% yield - and at $96.67 vs a 52-wk high of $126.62 it is the ONLY large energy name deeply off its highs, giving +29.1% to the $124.85 mean target, the widest in the section. TTM revenue -10.6% is the gas-price hangover the LNG-feedgas and data-centre demand curve is set to reverse.

Rev +64% / EPS +44%, fwd P/E 9.1 and P/B 1.35 - the cheapest large-cap US E&P - net debt ~1.4x EBITDA, Strong-Buy consensus (1.32) with +22.2% to the $59.81 mean target, the widest in the US Core lane; multi-basin short-cycle oil leverage is exactly what Oil SO(short) rewards. FCF conversion is the weak spot.

Rev +35.5% / EPS +107%, ROE 14.2%, net debt ~$15.6bn (D/E 36%), fwd P/E 14.4 on a 4.7% FCF yield; diversified low-cost E&P plus Alaska/Qatar LNG optionality fits Energy O/O/O, but at a 52-wk high with only +6.3% to target. (July row's banned 'Watchlist Candidate' verdict re-resolved per 4b.)

Fills the US LNG roster gap. ROE 39.1% on a ~95% take-or-pay contracted book, 75% operating margin, 13.3x forward, Strong-Buy consensus 1.41 and +12.1% to target; Corpus Christi Stage 3 trains are the dated catalyst. Consolidated leverage ~3.6x on the company basis (FMP's lease-inclusive 4.1x overstates it) - elevated but contracted, so no gate. Energy-security demand is a driver INDEPENDENT of Oil's U(long) tail.

Canadian-lane add (XEG #10). Lowest-cost Deep Basin gas producer: ROE 17.1%, 51% operating margin, 11.5x forward, FCF C$373m = 7.3% yield funding a 5.7% monthly dividend at a 56% payout, net debt ~1.35x EBITDA, +12.0% to target from 85% of its 52-wk high. Gas is a different driver from the Oil U(long) tail and benefits from LNG Canada pull on AECO.

Post-Veren scale shows as rev +86% / EPS +121%; net debt now only ~0.75x EBITDA (July's health flag has cleared), FCF C$1.48bn = 6.6% yield, Strong-Buy consensus 1.47 with +7.7% to target. Light-oil Montney/Duvernay short-cycle barrels fit Oil SO(short); 14.4x forward is the richest of the Canadian E&P peers.

Canadian-lane add (XEG #9). Net CASH (C$508m vs C$340m debt), rev +43%, 62% operating margins on Clearwater/Charlie Lake light oil, Strong-Buy consensus 1.40 and +18.8% to the C$16.15 target - the best short-cycle oil torque in the Canadian mid-cap tier under Oil SO(short). TTM net margin of 1.6% is hedge- and impairment-distorted, and 15.3x forward on P/B 3.7 is the richest Canadian E&P multiple.

Rev +44% / EPS +113%, net debt ~0.4x EBITDA (D/E 16%) - the strongest balance sheet in the section - 43 years of dividend growth plus ~$20bn/yr buybacks; but 15.3x forward and a 3.1% FCF yield is the dearest of the majors and only +3.8% to target. Guyana/Permian growth carries the Energy O/O/O signal.

Canadian-lane add (XEG #15) filling Canadian oilfield services. ROE 23.6% on an asset-light production-chemicals model whose revenue is recurring rather than rig-count-driven, rev +24% on US share gains, ~1.0x leverage, +14.3% to target. But TTM EPS -22%, a 3.3% FCF yield and 14.8x forward after a 128% run to a 52-wk high leave little margin; 8-analyst coverage caps confidence.

Rev +53% / EPS +322%, FCF $21.9bn = 5.2% yield, D/E 19%, 38 years of dividend growth and $2.5-3bn of buybacks a quarter; Hess/Guyana plus the Tengiz ramp is the best growth runway among the majors. But 15.8x forward with a 67% payout and only +3.7% to target leaves little asymmetry despite Energy O/O/O.

ROE 20.9%, interest cover 5.0x, net debt ~3.2x EBITDA, 5.7% distribution at a 75% payout; fee-based NGL/export model has LOW leverage to the oil shock that is driving the sector and only +5.8% to target - downgraded from July on driver fit, not on business quality.

⚠ caution: trades ~16% above the C$157.24 mean target; consensus Underperform (rec 3.72)

ROE 16.8%, near-net-cash balance sheet (D/E 17%), FCF C$4.6bn at a 37% payout and relentless Exxon-backed SIBs; but at C$181.84 it is ~16% ABOVE the mean target with an Underperform consensus and a 16.2x forward multiple - quality priced through, so Energy O/O/O cannot lift it past the caution gate.

⚠ caution: price ~3% ABOVE the C$32.80 mean target on thin 6-analyst coverage

ROE 16.5%, rev +53.6%, net debt ~0.85x EBITDA, FCF C$1.04bn = 5.4% yield at a 33% payout, Attachie phase 1 onstream; but at a 52-wk high the stock trades ABOVE its mean target on only 6 estimates, so the Montney/LNG driver has no discount left to work with.

Fills the oilfield-equipment roster gap (XLE #10 holding). Net cash ($17.0bn vs $16.3bn debt), ROE 16.5%, FCF $4.4bn = 6.9% yield, +12.1% to the $72.13 target - but revenue -2.4% and 20.4x forward is the OFS premium multiple. Its IET/LNG-equipment backlog is levered to gas infrastructure rather than to the Brent spike.

⚠ caution: trades ~14% above the $330.21 mean target on peak crack spreads

Best-in-class refiner - ROE 27.6%, FCF $8.4bn = 7.6% yield at a 19% payout, net debt only ~$3.5bn - and EPS +454% as cracks blew out. But at $385.62 (+151% off the 52-wk low) it is ~14% ABOVE consensus, and a crude spike compresses cracks unless products follow while Oil U(long) is the demand-destruction tail.

C$36.14 (52-wk 20.74-39.47), C$4.1bn cap, rev +17% with TTM EPS -27% and negative FCF while Blackrod phase-1 SAGD is built - first oil is the dated 2026-27 catalyst and a production step-change; Lundin-family control with ~20% of shares bought back. Oil-weighted, so Oil SO(short) helps, but yfinance has no .TO coverage (FMP-verified live) so confidence is capped.

⚠ caution: trades ~15% above the $340.56 mean target on peak crack spreads

ROE 42.1% (buyback-shrunk equity), FCF $9.2bn = 7.9% yield at a 14% payout and the sector's largest repurchase program; but D/E 133% on consolidated MPLX debt, and at $401.15 the stock is ~15% ABOVE the mean target with cracks at cycle peaks and Oil rated U long-term.

⚠ caution: negative FCF (-C$1.0bn) and dividend payout 217% of trailing EPS

D/E 8.2% - the least-levered Canadian gas producer - and fwd P/E 12.4 on a 5.5x forward EPS inflection, founder-led by Mike Rose; but TTM EPS -65%, FCF -C$1.0bn and a 217% payout. Gas/LNG-Canada demand is a genuinely different driver from Oil's U long-term tail, and at 88% of its 52-wk high it is one of the few names not extended.

⚠ caution: trades ~15% above the $93.93 mean target; consensus Hold (rec 2.63)

10.8x forward on a 10.6% FCF yield with ROE 19.5%, net debt only ~$1.1bn and ~10%/yr of stock retired; but the consensus is a Hold and the price sits ~15% ABOVE the mean target after a 137% run, with renewables still dilutive and cracks at peak. Refining is the sub-industry with the shortest runway under Oil U(long).

ROE 35.8%, near-net-cash, FCF $1.46bn, record subsea backlog converting at rising iEPCI margins - but revenue only +9% and the shares at 21.8x forward / 9.4x book sit slightly ABOVE the $75.81 mean target after a 122% run. Offshore is a long-cycle driver, and long-dated Oil is U.

Cheapest OFS name - 12.8x forward, PEG 0.77, 6.6% FCF yield - with ROE 14.9% and net debt ~1.75x EBITDA, and +16.3% to the $43.12 target from 85% of its 52-wk high. Offsetting that, revenue is only +3.7% because North American pressure pumping remains oversupplied; it is the OFS niche that responds LAST to $100 Brent.

July's revenue-decline caution gate has REVERSED - rev is now +53% and EPS +965%; ROE 10.6%, FCF $3.8bn = 6.2% yield, +9.3% to target. The most oil-price-geared large-cap through its balance sheet, but ~$10.5bn net debt plus the $8.5bn Berkshire preferred is the section's heaviest large-E&P load if Oil's U(long) demand-destruction tail arrives early.

Fills the royalty roster gap (XEG #8). 76% operating margin with zero capital or operating cost exposure - the purest price leverage in Canadian energy - rev +50%, essentially debt-free (D/E 6.9%). But 33x forward earnings is by far the section's richest multiple, the payout exceeds 100%, and at C$36.14 versus a C$36.79 target there is +1.8% left; the royalty structure is already fully paid for.

Fills the Canadian drillers roster gap (XEG-adjacent). Trades at book (P/B 0.99) and 10.1x forward with an 8.7% FCF yield, net debt ~1.26x EBITDA after early debt-reduction targets and ~10% of the float retired a year; +23.7% to the C$153.25 target is the widest upside of any Canadian name here. Against that: a TTM net LOSS, 3.2% operating margins and only 8 analysts - trough-cycle earnings levered to a Canadian rig-count recovery.

⚠ caution: trades ~10% above the $235.58 mean target

ROE 23.5% and EPS +345% on the crack cycle, FCF $4.5bn at a 28% payout; but the weakest margin capture of the three refiners, D/E 63%, an active Elliott campaign over midstream separation, and a price ~10% ABOVE consensus. Long-dated Oil U caps the refining thesis.

Revenue only +5% and EPS -30% as international activity softens and ChampionX is absorbed; ROE 12.9%, net debt ~1.55x EBITDA, 17.8x forward on depressed earnings with +8.1% to target. Service intensity should follow $100 Brent, but with a lag - the weakest fundamental momentum in the OFS group.

⚠ caution: leverage ~4.3x net debt/EBITDA and 91% distribution payout with IG Credit SU

Fwd P/E 12.4 / PEG 0.66 on a 6.3% distribution, rev +78% - but interest cover only 3.14x, ~$69bn net debt (~4.3x EBITDA on the FMP lease-inclusive figure) and a 91% payout; a fee-based sprawl with modest Brent torque, and the SU IG-credit signal is a direct headwind to the refinancing stack.

ROE 10.5%, net debt ~3.1x EBITDA, 21.7x forward with the C$2.94 dividend at ~101% of EPS (covered on a fee-based cash-flow basis); Cedar LNG on budget is the catalyst, but a contracted-tariff model captures little of a Brent spike and only +6.6% remains to the C$72.72 target.

⚠ caution: acquisition-levered balance sheet; FCF C$133m against a ~C$660m dividend

The Plains Canadian NGL acquisition drives rev +49% / EPS +116% and +13.0% to the C$64.27 target, but leaves D/E 161%, ROE 8.9% and free cash flow of only C$133m against a dividend near C$660m (payout 141% of EPS). NGL fractionation has some spread torque, but the funding profile is the binding constraint under IG Credit SU.

Canadian-lane add (XEG #17) and the only TSX producer with direct European gas (TTF) and Brent-linked pricing - the purest Canadian-listed play on an energy-security supply shock. Rev +23% and net debt ~1.3x EBITDA after divestiture proceeds, +9.7% to target. But TTM EPS -C$2.92 and ROE -18.5% on impairments, a shrinking production base and a history of strategy pivots and a dividend cut keep quality and management low.

⚠ caution: leverage ~3.9x net debt/EBITDA with FCF of only $66m after growth capex

Peer-lane add off the EPD/midstream cluster. Permian G&P volume leadership, but 24.2x forward, P/B 20 on a buyback-hollowed equity, ~$19.4bn net debt (~3.9x EBITDA) and free cash flow of just $66m after growth capex, with only +6.9% to target. Volume-driven, so it captures Permian activity rather than the crude price itself.

⚠ caution: net debt ~4x EBITDA with negative FCF (-$1.5bn) and dividend+capex coverage 0.69x

Fwd P/E 28.9 and P/B 7.0 on negative free cash flow, net debt ~4.1x EBITDA (FMP lease-inclusive basis), interest cover 3.3x; power-demand gas infrastructure is a real driver and +13.6% to target, but the fee-based model has little Brent leverage and IG-credit SU makes the funding gap the binding issue.

⚠ caution: leverage ~4.7x net debt/EBITDA and a payout ~98% of EPS with IG Credit SU

Regulated/contracted gas pipelines give ROE 11.8% and +13.4% to the C$99.52 target, and the South Bow spin removed the liquids drag - but ~C$61bn net debt (~4.7x EBITDA), 22.4x forward and a dividend at ~98% of EPS make it a bond proxy precisely when Long Treasuries and IG Credit are rated SU.

⚠ caution: leverage ~4.7x net debt/EBITDA, negative FCF and a payout ~148% of EPS against Long Treasuries SU / IG Credit SU

ROE 9.2% with TTM EPS -36%, FCF -C$1.1bn, ~C$110bn net debt (~4.7x EBITDA) and a 5.6% dividend costing ~148% of EPS; the most rate-sensitive name in the section exactly as Long Treasuries and IG Credit are rated SU. At 86% of its 52-wk high with +14.7% to target it is cheap for a reason, not by oversight.

Fills the US drillers roster gap. TTM EPS -$1.39 and ROE -4.6% after the debt-funded KCA Deutag impairment, revenue -0.6%, and the price sits exactly ON the $44.00 mean target with a 2.50 consensus. The 11.2% FCF yield and 2.3x leverage are the offsets. US land day-rates should follow $100 Brent, but rig-count response lags the price by quarters - honest roster coverage, not a recommendation.

P/E 11.6 (fwd 10.0) and ~1.1-1.2x P/NAV — V anchored on P/NAV not earnings; FCF C$3.0bn, net cash C$1.9bn, ROE 37%; +23% to a C$51.90 consensus, 21% off the 52wk high. Gold SO/SO/SO with gold +22% y/y and recovering off the July low: the cheapest senior with full price leverage.

ROSTER GAP FILLED (mid-tier gold was entirely absent in July). ROE 27%, 67% operating margin, net cash C$460m, EPS +69%; P/E 13.3 / PEG 0.99 and ~1.1x P/NAV after a 32% drawdown from the 52wk high, with +28% to a C$65.87 consensus — the best quality-plus-discount combination in the gold complex. All-Canadian assets. Gold SO/SO/SO.

Best-in-class operator: 58% operating margin, ROE 23%, FCF C$4.3bn, net cash C$3.2bn. But V on P/NAV is the sector's richest premium (~1.5-1.7x, P/E 17.4) and the C$284.66 mean target sits at the share price — all driver, no discount. Gold SO/SO/SO; Tier-1 Canadian jurisdiction.

ROSTER GAP FILLED (royalty/streaming had only WPM). 77% operating margin, ZERO debt, C$1.0bn cash, revenue +58%; the purest cost-inflation-immune model in Materials. But P/E 34.8 / ~1.6-1.8x P/NAV is the section's richest and the C$386 mean is only +5% away. Gold SO/SO/SO.

ECONOMIC STUDY CONFIRMED: Panuco Feasibility Study, Nov-2025 — after-tax NPV5 US$1.8bn, IRR 111%, 7-month payback, 17.4 Moz AgEq/yr over 9.4 years at US$35.50/oz Ag and US$3,100/oz Au; still robust at US$17 Ag (NPV US$460m, IRR 42%). EV C$1.82bn vs a C$2.5bn study NAV = ~0.73x at deck, far lower against ~US$66 spot silver. C$411m cash vs C$240m debt — funded; construction 2H-2026, first production H2-2027. 42% off the 52wk high, +30% to consensus. Silver O/O/O: the best silver asymmetry in the section.

Revenue +85%, EPS +86%, 72% operating margin; a streamer pays a fixed cost per ounce, so the energy shock hits its counterparties' diesel bill, not its own — the structural edge in this regime. V is the constraint: P/E 34.9, ~1.7x P/NAV, +9% to a C$236.93 consensus. Gold SO + silver O.

CLEAN-EARNINGS FLAG: pretax margin 61.0% vs operating margin 51.4% — non-operating (divestiture) gains are ~16% of pretax, so V and G are scored on operating EPS ~US$6.68 (P/E ~19.5x, not the headline 16.4x). P/NAV ~1.3x after a 71% 12mo run; only +2% to a US$132.87 consensus. Strongest RS in the group (4% off the 52wk high). Gold SO/SO/SO.

ROE 45%, 51% operating margin, FCF US$4.0bn, 4.2% yield; P/E 14.7 / PEG 0.78 and ~1.0x P/NAV — the African jurisdiction discount is the asymmetry. Only +3% to the US$113 mean. Gold SO/SO/SO.

Peer-lane add off NEM. Revenue +116% on the Sandstorm + Horizon Copper acquisitions; 62% operating margin, fwd P/E 20.5 / PEG 1.06 — the cheapest of the three streamers, +15% to a US$302.67 consensus. Same energy-shock cost immunity as FNV/WPM. Gold SO/SO/SO.

Absorbed MAG Silver in Sep-2025 (44% of Juanicipio) — revenue +38%, EPS +39%, net cash C$864m. Fwd P/E 11.3 / ~0.9x P/NAV after a 23% drawdown, +25% to a C$92.07 consensus. Silver O/O/O plus a gold SO sleeve; the offset is that silver is 44% below its January peak even after +65% y/y.

ECONOMIC STUDY CONFIRMED: Eskay Creek Definitive Feasibility Study (Nov-2023, updated) — after-tax NPV5 C$2.0bn, IRR 43%, pre-production capex C$713m, 1.2-year payback, NPV:capex 2.8:1. STAGE RE-CLASSIFIED Speculative -> Growth: construction is complete and the company guides ~290koz Au and ~C$685m operating cash flow in 2026 at ~0.7x P/NAV on its own basis (fwd P/E 10.3). Net debt C$973m and FCF -C$859m through the build are the risk; 8/8 analysts Strong Buy, +14% to target. Gold SO/SO/SO on a brand-new Canadian producer.

Cheapest senior on P/NAV (~0.9-1.0x, P/E 11.6) because Mali/Loulo-Gounkoto is still seized; FCF C$5.1bn, net cash C$1.25bn, EPS +55%. Non-operating income is not material here (unlike NEM). Gold SO/SO/SO — the jurisdiction discount IS the asymmetry; +12% to the median target.

ECONOMIC STUDY CONFIRMED: Cabaçal Pre-Feasibility Study, March-2025 — after-tax NPV5 US$984m, IRR 61.2%, ~141koz AuEq/yr over ~10 years; shallow high-grade low-strip VMS, sub-2-year payback (top-quartile developer economics). EV C$854m = ~0.63x PFS NAV; C$96m cash and ZERO debt; DFS due Q4-2026 and the Installation Licence pending. +59% to a 9-analyst C$3.09 consensus. Gold SO/SO/SO is the dominant metal with copper second — the cleanest developer asymmetry in the section. Build financing is the dilution risk.

Côté Gold ramp delivered: revenue +48%, EPS +191%, FCF C$1.22bn, net debt now ~nil. P/E 10.5 / fwd 8.7 with +14% to a C$32.75 consensus. Quality and management scored down for the Côté capex blowout history and above-average AISC. Beta 2.34 — maximum leverage to a gold SO/SO/SO signal.

Forward P/E 5.3 — the cheapest gold producer in the section — PEG 0.89, EPS +185% as Goose (Nunavut) ramps; +22% to a C$9.37 consensus. Q and M carry the Fekola/Mali jurisdiction risk and the Goose capex history; net margin 21% trails the seniors. Gold SO/SO/SO.

D RAISED 61->76, the section's honest energy-shock WINNER: CF's feedstock is US Henry Hub gas while the marginal global ammonia producer is European gas-based, so a Hormuz shock widens its cost advantage rather than compressing it — and the tape agrees (3% off the 52wk high with a 0.40 beta while the chemicals complex is 15-31% off). ROE 30%, 49% operating margin, US$1.3bn FCF, net debt ~0.4x EBITDA, share count down ~30% over five years. V is the brake: forward P/E rises to 13.3 from 10.2 trailing (consensus expects the spread to normalise) and the price sits ~9% above the US$125.04 mean. Agriculture O/O/SO.

Fruta del Norte is the sector's lowest-cost mine — ROE 101%, 66% operating margin, FCF C$999m, net cash, 5.9% yield. But it is a SINGLE asset in Ecuador, revenue grew only 5.5%, and the C$96.25 mean target equals the share price. Gold SO/SO/SO carries it; concentration and zero upside cap it.

Tucumã at nameplate took revenue +74%; ROE 31%, 38% operating margin, fwd P/E 8.2. Net debt C$472m and a year-late ramp keep H and M down, and the price now sits ~4% ABOVE the C$51.49 mean target (below the C$61 high, so no gate). Copper U(short)/N(medium)/SO(long): the tape is at 52wk highs and +48% y/y, but a producer's near-term cash flow is what the short-U call is about.

⚠ caution: EV ≈ 5.7x the 2024-UFS NAV (≈1.5x re-decked to spot gold); only +6% to consensus after a +240% 12-month run

ECONOMIC STUDY CONFIRMED: Koné Updated Feasibility Study (Jan-2024) — after-tax NPV US$1.089bn, IRR 31%, capex US$712m (revised budget ~US$885m), 16-year life, >300koz/yr for 8 years, AISC ~US$998/oz. Built ahead of schedule and on budget; first gold pour late Q4-2026. But EV C$8.5bn against a C$1.5bn study NAV leaves nothing to buy, and a bulk-tonnage open pit at ~US$1,000/oz AISC is the most diesel-intensive mine type in a Brent>$100 world — that cost exposure is why Q is marked down from a headline-execution read.

ROE 24%, 44% operating margin, net debt ~nil, revenue +38%. Forward P/E 18.9 exceeds the trailing 17.2 — consensus expects earnings to fall — and only +11% to a C$41.34 mean. The real asset is the Vicuña (Filo/Josemaria) JV with BHP, which pays into the long-SO copper window, not the short-U one.

Net debt cut to ~nil, ROE 17%, 33% operating margin, 21 analysts at Strong Buy (1.43), Copper World permitted. D sits above the pure-copper names because ~30% of revenue is GOLD (Snow Lake), which inherits the SO signal while the copper book carries the short-U. P/E 17.7 / fwd 15.0 is not cheap and the C$41.94 mean is only +5% away.

Revenue +139% as Terronera commissions and Kolpa is absorbed; net debt ~nil, +30% to a C$20.10 consensus. But net margin is only 8.9% and ROE 10.6% in the ramp year, Terronera's capex overran materially, and the forward P/E of 9.1 depends entirely on the ramp delivering. 25% off the 52wk high. Silver O/O/O — the highest silver-price leverage among the producers.

⚠ caution: EV ≈ 5.4x the starter-case PFS NAV; +11% to consensus after a +273% 12-month run

ECONOMIC STUDY CONFIRMED: updated Cuiú Cuiú PFS, 29-Jul-2025 — IRR 78%, after-tax NPV5 US$73.9m at US$2,500/oz, capex US$37.7m, ~10-month payback. Fully funded by a drawn US$45.1m gold loan; first production/ramp Q4-2026 with no delays. Excellent starter economics, but EV ~US$400m is ~5.4x that starter NAV — the case now rests on spot gold (~1.75x the study deck) plus an unquantified hard-rock resource, i.e. optionality rather than NAV. D/E 389% pre-revenue. Gold SO/SO/SO.

Mantoverde ramping: revenue +36%, EPS +224%, fwd P/E 11.7, PEG 0.30, +10% to a C$17.58 mean. Net debt C$1.20bn (~2x EBITDA) and a ramp that ran late are the constraints; Santo Domingo is the next leg. Copper U/N/SO — a volume-growth story whose ounces arrive in the long-SO window.

ECONOMIC STUDY CONFIRMED (the study a prior run missed): Ausenco PEA on the 'Combined Strategy', 22-May-2025 — after-tax NPV7 C$169m (headline C$171m), IRR 36%, initial capex just C$64m at a US$4.25/lb Cu deck. NPV:capex 2.6x, the hallmark of a brownfield restart, and CCI now OWNS the permitted Caribou process plant outright (title transferred 28-Jul-2026 for ~C$6.2m). EV ~C$146m = ~0.86x the deck NAV and cheaper still against copper at 52wk highs (+48% y/y, above the US$4.25 deck). C$64m of capex against a C$146m company is the dilution risk; EIA in review. Copper U(short)/N/SO(long).

ROSTER GAP FILLED (silver producers). SilverCrest/Las Chispas took revenue +126% and produced US$797m FCF and a first net-cash balance sheet in a decade. CLEAN-EARNINGS FLAG: net margin 26.8% exceeds the 19.4% operating margin (tax-driven), so V is scored on operating EPS ~US$0.86 (P/E ~24.7x, not 17.9x). Operating margin is the weakest of the silver producers. Silver O + gold SO.

Peer-lane add off FCX; VALIDATED LIVE — this is the former Taseko Mines, renamed Trekor Metals (TSX: TKO / NYSE American: TGB), holding 75% of Gibraltar plus Florence Copper, Yellowhead, Aley niobium and New Prosperity. Florence's ISR ramp drove revenue +185%, fwd P/E 11.1, PEG 0.34. Net debt C$578m, FCF -C$104m and a 1.6% net margin cap it. Copper U/N/SO — low-cost US domestic ISR copper also carries a critical-minerals policy angle.

ECONOMIC-STUDY CHECK, BOTH WAYS: flagship Gaspé Copper has NO economic study yet — a PEA is targeted for 2026 following an updated MRE (14-Apr-2026: M&I 1.83 Bt @ 0.27% Cu after 118,000m of 2025 drilling) — but the company DOES carry a filed study on the Pine Point zinc JV with Appian (2022 PEA: after-tax NPV C$602m @8%, IRR 25%, capex C$653m, 12-year life). Grade is low at 0.27% Cu; past-producing brownfield infrastructure and scale are the offset. C$105m cash; +66% to an 8-analyst C$2.82 consensus. The Gaspé PEA is the thesis-defining 2026 catalyst. Copper long-SO.

P/E 14.0, 4.5% yield, ROE 19%, net debt ~0.7x EBITDA; but the US$104.09 mean target equals the share price. NOTE ON D: iron ore carries NO signal in the current macro block, so facet (a) is scored off the COPPER (Oyu Tolgoi ramp) and bulk mix plus XLB 'O' — not an invented iron-ore call. Aluminium is a cost-side negative in an energy shock; Arcadium/lithium timing and Simandou capex weigh on M.

D CUT 73->54. On-site take-or-pay contracts pass energy costs through, which protects the MARGIN — 28% operating, ROE 18.4%, US$4.2bn FCF, best-in-class allocation — but industrial-gas VOLUMES track industrial production, which an energy-shock stagflation compresses, and the XLB 'O' signal is being driven by the metals complex, not by chemicals. P/E 30 / PEG 1.85 is still a premium after a 15% drawdown; +17% to a US$544.54 consensus is the offset.

Largest US primary silver producer (Greens Creek, Lucky Friday) — revenue +52%, EPS +93%, net cash US$464m. But P/E 25 / fwd 20 is rich versus the gold seniors, ROE 22% flatters a long record of write-downs, and Keno Hill is still loss-making. 39% off the 52wk high. Silver O/O/O + a domestic critical-minerals angle.

ROSTER GAP FILLED (packaging had zero coverage; XMA holding, GICS Containers & Packaging sits in Materials — the provider's 'Consumer Cyclical' tag is a classification difference). One of Canada's best serial acquirers: 15.4% operating margin, ROE 14.7%, C$867m FCF, net debt ~1.4x EBITDA, beta 0.64, +18% to a C$108.10 consensus. D is the brake: labels ride Staples volumes (rated U/U/U) and resin/film substrates are oil-derivatives whose cost rises directly with Brent.

⚠ caution: px US$211.30 > highest analyst target US$178 (valuation extreme); consensus recommendation is Underperform

The best cost position in copper — ROE 50%, 61% operating margin, US$5.0bn FCF, revenue +41%, EPS +72%. And entirely in the price: P/E 31.7, P/B 14.4, and the shares trade 19% ABOVE the highest published target (FMP consensus US$162.33, high US$178) with the consensus at Underperform. Copper U(short) with zero asymmetry left — the 'expensive quality' case.

Best margins of the diversifieds (43% operating, ROE 24%) and net debt ~0.5x EBITDA, but EPS is DOWN 9% and P/E 24.0 is the richest of the group. TARGET DATA UNRELIABLE — FMP consensus US$95 vs Yahoo mean US$74.36/high US$91 on mixed listing bases, so NO valuation-extreme gate is fired on it (a false gate avoided); V is marked down on the multiple instead. D scored off copper (U/N/SO) plus unsignalled iron ore and Jansen potash into an Agriculture-O window.

Best returns in US steel (ROE 17.6%), revenue +33%, EPS +84%, forward P/E 12.7 with +12% to a US$271.21 consensus. Sinton plus the new Columbus aluminium rolling mill add volume into tariff-protected domestic demand; FCF is thin at US$234m during that build. Same demand-side headwind as Nucor: SU Real Estate, SU Consumer Discretionary, rising power costs.

⚠ caution: pre-resource — no compliant MRE and no economic study; C$662m cap on an exploration target

ECONOMIC STUDY — CONFIRMED ABSENT, and there is no compliant MRE either (checked company disclosure + coverage, not assumed). Salvadora (9,062 ha, Atacama, Chile, 15km from Codelco's El Salvador) is in Phase-6 drilling; Argonaut raised its target to C$13.40 on 4-Jun-2026 and lifted the San Juan exploration target from 2.0 to 3.5 Moz, flagging a possible ~10 Moz district. C$23.8m cash, zero debt, ~C$4.6m burn = ~5 years of runway (unusually strong for the stage). But the shares are +1,170% in 12 months and a C$662m cap already capitalises an exploration TARGET — gold SO/SO/SO cannot supply a NAV that does not exist.

JULY GATE CLEARED: the 'cyclical trough negative FCF' flag is resolved — FCF is +US$683m, EPS +94%, revenue +23%, net debt ~1.0x EBITDA. EAF flexibility and scrap (not oil-linked) feedstock are a genuine relative advantage in this regime, and Section 232 at 50% supports pricing. But steel demand is construction and autos — Real Estate SU and Consumer Discretionary SU — and EAF power costs rise with the shock, so D stays middling.

Revenue +57% and EPS +102% on the Gatos deal, net cash US$917m; but ROE is only 13%, net margin 21%, and P/E 30 / fwd 21 is expensive for that quality. Chronic AISC overruns and serial dilution keep Q and M low. 34% off the 52wk high, thin coverage (2 analysts). Silver O/O/O.

ⓘ note: earnings-integrity limb examined and found not to bite here. Section 4a enumerates three things — "mark-to-market gains on equity stakes, 'other income,' one-off gains" — so bare "other income" IS on the list; the screen declines to read it literally in this row because the purpose test fails. Its stated rationale is that an inflated EPS makes a dear name look cheap, and the distortion here runs the other way. The income is recurring and economically core rather than a revaluation or a windfall, so it is disclosed rather than gated, and where that boundary sits is now written into section 4a's character clause rather than left open.

Revenue +58% as Platreef Phase 1 and Kipushi ramp, but the Kakula flooding/seismic event crushed 2026 economics — operating margin 6.3%, ROE 2.1%, FCF -C$310m — and the guidance resets damaged credibility. 34% off the 52wk high. Kamoa-Kakula is the highest-grade major copper mine on earth: DRC jurisdiction and power constraints are the risk, and the long-SO copper window is exactly where that asset pays. Earnings basis, previously undisclosed and added at audit: reported profit runs well above operating income because Kamoa-Kakula is held in a joint venture and its earnings arrive BELOW the operating line as an equity-accounted share of profit — Q2'26 operating $11.2m against net $49.7m, and Q4'25 operating -$24.4m against net +$54.7m. That is recurring income from the company's principal asset, not a mark-to-market gain, so it is not gated; but it does mean trailing earnings are not the valuation basis. Trailing P/E is 112.6 against forward 23.8, so the distortion makes the name look dearer, not cheaper, and V is scored off forward earnings and NAV.

Revenue is DOWN 7.3% — the Grasberg mill incident and force majeure are still working through — and the trailing P/E is 37.7 against a 18.6 forward. Interest coverage 16x and net debt ~0.6x EBITDA are fine; the problem is that at US$76.93 the price is ~6% above the US$72.05 consensus mean. Copper U/N/SO.

JULY CAUTION GATE RESOLVED: interest coverage is now 4.08x (was 1.6x, near the 1.5x hard gate) and net debt is ~0.3x EBITDA with US$1.63bn cash and a 2.09 current ratio — H rises from 45 to 78. Revenue +31% as lithium turns; trailing P/E 264 is meaningless, fwd P/E 11.2 / PEG 0.79 on a recovery estimate, +36% to a US$172.56 consensus, 43% off the 52wk high. Net margin 3.8% is still trough-level. Lithium is unsignalled; the energy-transition driver is intact but SU Consumer Discretionary is a poor backdrop for EV units.

ROSTER GAP FILLED (specialty chemicals; XLB's #7 holding was absent). The most annuity-like revenue in the chemicals block — embedded service model, 22% ROE, disciplined M&A, data-centre water as a new growth leg. But P/E 36.8 / PEG 2.52 is the richest multiple in the section and its end-markets (hospitality, foodservice, commercial buildings, light industry) are precisely what a stagflation squeezes; cost pass-through works with a lag.

⚠ caution: px US$71.00 > highest published target US$69.43 (FMP consensus US$68) — valuation extreme; equity pinned by the pending Anglo Teck merger of equals (completion expected ~Sep-2026), a merger-arb binary rather than a commodity call

SPECIAL SITUATION: the merger of equals with Anglo American (announced 9-Sep-2025) has Investment Canada Act approval and shareholder support, with the letter of transmittal mailed and completion expected around September 2026. QB2 at capacity took revenue +78% and EPS +324%, but ROE is only 8.7% after the capex overrun and the share price already exceeds every published target because it tracks the exchange ratio. Copper U/N/SO plus zinc — but the commodity is not what sets this price today.

HONEST NEGATIVE-D ADD (peer lane off FCX). Cheap and well-capitalised — P/E 10.5 / fwd 8.7, revenue +31%, EPS +147%, net debt ~0.3x EBITDA, +24% to a US$62.98 consensus after a 40% drawdown. But aluminium smelting consumes ~14 MWh per tonne, making it the most electricity-intensive process in the sector: an energy shock attacks the cost line directly. Aluminium carries NO macro signal, so D is scored off that power-cost mechanism plus the copper/industrial-metals short-U read — marked down, not invented. Section 232 and Chinese capacity caps are the price-side offset.

⚠ caution: EV/Sales ≈ 31x with a NEGATIVE gross margin — the equity capitalises a policy outcome, not cash flow

ROSTER GAP FILLED (rare earths, beyond ALB). Revenue +120% as the Independence magnet line ramps under a DoD price-floor and equity package plus an Apple magnet agreement — genuinely strong strategic execution, 16 analysts at Strong Buy, +37% to a US$75.38 consensus, 45% off the 52wk high. But gross margin is NEGATIVE, operating margin -33%, and EV/Sales ~31x. US$1.45bn cash gives ~3.3 years of runway, so no burn gate. D is carried by Defense O/O/SO and critical-minerals policy, not by a commodity signal.

Revenue -1.2% and EPS -9.9% as crop-protection pricing keeps deflating; 30% operating margin and a real seed-genetics moat, but ROE 4.3% after intangible amortisation and a 20.7x forward multiple for that growth. The announced seed / crop-protection separation is a credible 2027 value-unlock. Agriculture O/O/SO helps farm income, but crop protection is an energy and feedstock COST TAKER in this regime.

⚠ caution: provider total-debt US$110bn is provision/lease-inclusive — reported expanded net debt ~US$25bn ≈ 1.8x EBITDA; Mariana/Samarco settlement is the real overhang

DATA-BASIS TRAP CHECKED: the provider debt figure is lease- and provision-inclusive, so NO hard leverage gate is fired on it — reconciled expanded net debt is ~US$25bn (~1.8x EBITDA), not the headline US$110bn. Cheapest major on fundamentals: fwd P/E 7.85, PEG 0.33, P/B 1.69, 7.65% yield; ROE 4.1% and EPS -44% are depressed by settlement charges. D off the copper/nickel pivot plus EM equities U/N/O — iron ore is unsignalled and not invented.

Revenue +4% and EPS +1.2% — the retail arm dilutes potash's margin structure (ROE 9.4%, operating margin 17.5%), net debt ~2.5x EBITDA is the highest in the fertilizer group, and the price sits above the US$76.43 consensus mean. Agriculture O/O/SO supports potash, but Nutrien lacks CF's Henry Hub edge and is gas- and freight-cost exposed on the input side.

⚠ caution: no economic study on either asset — no NAV anchor

ECONOMIC STUDY — CONFIRMED ABSENT (checked, not assumed): the Excelsior stockpile carries a compliant NI 43-101 inferred MRE of 42.9 Moz Ag but NO PEA/PFS/DFS, and flagship Quiulacocha has no compliant resource at all (maiden MRE targeted H2-2026, 116 holes drilled). With no published NPV there is no P/NAV to discount, so ~C$496m EV is fully priced for the stage. C$22.4m cash, ~18-month runway. Silver O/O/O supports the theme; the missing study caps it.

⚠ caution: ~C$2.7m cash vs ~C$7.4m/yr burn (<6-month runway) — a heavily dilutive financing is imminent

JULY READ REVERSED — ECONOMIC STUDY CONFIRMED: New Polaris Feasibility Study filed — after-tax NPV5 US$425m / IRR 30.9% at US$2,500/oz, rising to US$793m / 47.3% at US$3,300/oz; capex US$250m, AISC US$1,247/oz, ~806koz over 8.3 years. BC environmental-assessment application filed March-2026 and listed as a provincial priority. EV ~US$105m = ~0.25x the base-deck NPV and ~0.13x the US$3,300 case, against ~US$4,375 spot gold — the deepest study-backed discount in the section (D 72->82, Q 30->60). What caps it is the treasury: ~C$2.7m of cash against a ~C$7.4m annual burn and US$250m of unfunded capex.

ECONOMIC STUDY — CONFIRMED ABSENT (checked, not assumed). Maiden MRE delivered 20-Jan-2026: 2.33 Mt Indicated @ 1.41% Cu at Kazhiba Main (oxide, near existing Solwezi infrastructure), with Dumbwa extended to 6.7km of strike. Good grade for a potential near-term heap-leach, but 2.33 Mt is a small starting resource and no economics have been published. C$18.2m cash, ~18-month runway, no debt. Shares 66% off the 52wk high; the +316% to a 2-analyst target is optically large but has no NAV behind it. Copper U/N/SO.

⚠ caution: net debt ≈ 3.3x EBITDA with NEGATIVE tangible book value (-US$32.57/share)

D CUT 73->36 — both blades of the scissors close at once: architectural coatings are levered to housing turnover and remodelling (Real Estate SU/SU/SU, Consumer Discretionary SU/SU/SU) while resins, solvents and TiO2 are oil-derivatives whose cost rises with Brent. A real store-network moat and 49% gross margin, but 11% net margin, P/E 29.8 / PEG 2.15 for a contracting end-market, and leverage that now costs more. Coverage is still 7.7x, so caution not hard.

⚠ caution: coverage basis UNRESOLVABLE on the EBITDA leg — EBIT-cover is ~1.1x (below the 1.5x line) but EBITDA-cover cannot be struck this cycle: the .TO fallback carries no interest-expense field and a quarter is missing, so the second basis the revised test requires is unavailable rather than passing. Declared unresolvable and capped, not cleared. Net debt C$6.9bn ≈ 3.1x EBITDA (below 4x), TTM net loss; the Cobre Panamá restart is a binary.

Kansanshi S3 lifted revenue +24%, but the TTM line is a net loss (ROE -1.2%) because Cobre Panamá — the largest asset — remains suspended. Net debt C$6.9bn and EBIT-basis coverage of ~1.1x sit just inside the hard gate (EBITDA-basis coverage ~4x, leverage 3.1x, so this is caution not distress). A restart would re-rate the equity hard; that binary is the whole D case alongside copper's long-SO window.

ECONOMIC STUDY — CONFIRMED ABSENT, and no compliant MRE (checked, not assumed). Gold Rock camp, Dryden Ontario: high-grade hits (32.87 g/t over 4.25m; 8.68 g/t over 9.40m at Jubilee) and two new structures at Gold Rock in Jul-2026, with 23,000-25,000m planned on a ~US$10m 2026 budget. Data are thin (no cash/debt in the pull) and the shares sit 42% off the 52wk high near the low. Gold SO/SO/SO is the only support — pre-resource, so there is no NAV to discount.

⚠ caution: net debt ≈ 3.8x normalised EBITDA (below the 4x line; 4x alone is a caution under the revised rule, not a hard gate); FCF -US$1.5bn; TTM operating loss on ~US$3bn of project write-offs

D CUT 73->46. Same volume headwind as Linde but on a levered balance sheet: TTM operating margin is -4.7% on green-hydrogen write-offs, FCF is -US$1.5bn against project capex, and net debt is ~3.8x normalised EBITDA — inside the 4x line, and in any case 4x alone is now a caution rather than a hard gate. The activist board change in 2025 happened precisely because of capital misallocation, and an energy shock does not rescue electrolytic hydrogen: high power prices raise its cost. +15% to a US$343.63 consensus on a reset earnings base.

⚠ caution: TTM net loss; operating-income interest coverage 0.73x (EBITDA-basis ~7.5x, net debt ~3.3x EBITDA) — impairment-distorted, not distressed

The weakest P&L in the section: revenue -6%, a TTM net loss, 1.4% operating margin, FCF -US$746m, and the US$26.47 mean target equals the share price. P/B 0.73 is genuinely cheap on assets but there are no earnings to anchor a multiple. HARD GATE NOT FIRED — the 0.73x coverage is on impairment-hit operating income; on EBITDA it is ~7.5x with 3.3x leverage. Agriculture O/O/SO helps pricing, but ammonia and sulphur are Mosaic's two largest phosphate inputs and both track gas and oil, so it is a cost-side LOSER in an energy shock.

⚠ caution: cyclical trough — TTM operating loss and FCF -C$424m; net debt only C$317m vs ~C$7.6bn equity, so leverage is far below the 4x line; EBIT-cover fails at the trough and the EBITDA leg is not strikeable on the .TO fallback, so the coverage basis is declared unresolvable and capped rather than argued away

ROSTER GAP FILLED (forest products had zero coverage) — and it scores as the WORST-placed name in the section, which is the point of running the lane. TTM EPS -C$21.23, net margin -23%, revenue -6.4%, FCF -C$424m. Lumber and panel demand is housing starts and repair-and-remodel (Real Estate SU/SU/SU, Consumer Discretionary SU/SU/SU) while diesel, resin and freight costs all rise with Brent — both sides of the margin move the wrong way. Management closed capacity early and kept the balance sheet clean (net debt only C$317m vs C$7.6bn equity), which is why the coverage limb caps rather than hard-gates; only 2 analysts cover it.

⛔ hard: net-debt/EBITDA ~6.6x above the 4x line AND debt service impaired on BOTH bases — EBIT-cover -0.04x and EBITDA-cover 2.64x, against thresholds of 1.5x and 3.0x. A genuine operating shortfall, not a depreciation artifact.

ROSTER GAP FILLED (commodity chemicals) — and it fails on merit, which is the honest result. TTM net loss of -US$1.70/share, EBITDA margin 5.6%, interest coverage -0.04x, net debt ~US$15.2bn ≈ 6.6x EBITDA, and a dividend that was defended out of losses before being cut. Commodity chemicals is the worst-placed sub-industry for this regime: naphtha/ethane feedstock and energy costs rise with Brent while the demand side (construction, autos, packaging, durables) is exactly what SU Consumer Discretionary and SU Real Estate describe. P/B 0.86 is cheapness that the leverage owns.

⛔ hard: delisted/unresolvable

DELISTED — Pan American Silver completed its acquisition of MAG Silver (44% of Juanicipio, plus Larder and Deer Trail) and MAG shares were delisted in September 2025. Yahoo returns no data for MAG or MAG.TO. Carried in July in error; the exposure now sits inside PAAS.TO. Remove from the universe.

Rev +47.7% and EPS +26.2% TTM, op margin 54.2%, ROE 102%; fwd P/E 23.7 / PEG 1.11, ND/EBITDA ~1.0x, +17% to $1,316 consensus. GLP-1 is the sector's strongest secular driver but obesity scripts are semi-discretionary for a squeezed household; Health Care N/N/N.

Rev +66.9% on the Amvuttra ATTR-CM launch with op margin 17.9% and ROE 96.6%; fwd P/E 20.4 / PEG 0.34, roughly net-cash. Down 49% from the 52wk high on ATTR-CM share doubt (BridgeBio, Pfizer) yet +45.7% to $371.35. Roster gap: large-cap biotech.

Rev +18.5%, EPS +26.5%, op margin 33.6%, ZERO debt and $5.2bn cash. The -42% de-rate from $603.88 takes fwd P/E to 29.1 / PEG 1.60 and opens +36.1% to $478. Offset in D: robotic-surgery volumes are partly deferrable elective procedures and hospital capex is tightening.

Rev +16.7% (Dupixent + Eylea HD recovery), op margin 33.1%, net CASH $5.3bn, fwd P/E 13.4 / PEG 1.17. Founder-led science and heavy buybacks; the constraint is only +4.8% to $844.87 after a run from $541.

July's PEG-2.3 caution gate CLEARS: at the 52wk low ($271.31), -30% from high, PEG is 1.29 and fwd P/E 16.4 (FY27 consensus EPS 16.75 confirmed via estimates). Rev +9.4%, op margin 27.0%, ND/EBITDA ~1.7x, +37.2% to $377.84.

Rev +6.4%, op margin 23.5%, ROE 22.0%, fwd P/E 13.9 / PEG 1.26, ND/EBITDA ~1.9x. Sits near its 52wk low ($145.80) with the widest large-pharma upside at +34.9% to $212.54 and a strong-buy consensus (1.45).

Restaged Established (a $132bn profitable mega-cap growing 12.5%, not a Growth-stage name). Op margin 38.1%, ROE 23.5%, net cash $5.9bn, near-monopoly CF franchise; Journavx non-opioid pain launch is the catalyst. Fwd P/E 25.8 / PEG 1.67 is the brake.

Rev +10.2%, op margin 33.7%, FCF yield 5.4%, fwd P/E 14.7, ND/EBITDA ~2.1x. Lenacapavir/Yeztugo HIV-prevention launch is a dated catalyst; HIV is about as non-discretionary as pharma gets. Only +8.0% to $157.41 caps the upside facet of D.

Roster gap: cardiovascular devices. Rev +13.6% on TAVR/structural heart, op margin 29.8%, net CASH $3.5bn. TAVR is genuinely non-deferrable (untreated severe aortic stenosis is fatal), so it scores a better driver than ortho. Fwd P/E 25.5 / PEG 1.92 is full; +17.0% to $100.96.

Rev +6.6% but EPS -0.9%; op margin 29.2%, ROE 25.7%, ND/EBITDA <1x (best balance sheet in the sector). Priced to consensus at +2.7% to $276 and near the 52wk high; fwd P/E 21.8 / PEG 4.38 leaves no upside facet in D.

Peer-lane add off ISRG. Rev +13.1%, EPS +43.6%, op margin 24.3%, ROE 38.5%, net cash, recurring sensor razor/blade. Fwd P/E 27.0 / PEG 1.35 is full and only +11.5% to $94.12; GLP-1 substitution is a live driver risk against reimbursed CGM demand.

Roster gap: distribution - the best stagflation profile in the sector (fee-for-service on units, contractually inflation-indexed, no discretionary exposure, GLP-1 unit tailwind). Rev +7.7%, FCF yield 6.5%, ND/EBITDA ~1.2x, share count down ~40% over a decade. Fwd P/E 17.7 / PEG 1.71 and +9.8% to $980.73.

Rev +10.2% on the Skyrizi/Rinvoq ramp, op margin 40.0%, FCF yield 3.8%, fwd P/E 15.3. ND ~$64bn (ND/EBITDA ~2.5x) against negative book equity; +10.9% to $277. Immunology demand is non-discretionary — a fair stagflation profile.

Op margin 34.6%, ROE 30.4%, FCF yield 4.6%, div 3.4%, fwd P/E 14.0. But rev +0.8% and EPS -17.0% into the Entresto/Tasigna LOE; consensus rec 2.75 (hold) with +14.1% to $156.92. Roster gap: non-US large-cap pharma.

Pre-revenue: $502m cash vs ~$231m/yr burn = ~26mo runway, essentially no debt. The VK2735 oral/subcutaneous obesity programme is the catalyst (late-stage; exact trial status not live-verified this cycle); 19 analysts, strong-buy 1.45, +182% to $92.39. Single-asset binary plus a financing need are the risks.

⚠ caution: sustained negative estimate revisions - fwd EPS 3.42 below trailing 4.08

Op margin 42.5% and ROE 59.8% still exceptional, ND/EBITDA <1x, trailing P/E 11.0 and div 4.0%. But rev +2.1%, EPS -20.6% and forward EPS BELOW trailing: on the losing side of the obesity driver (US net-price deflation, share loss to LLY), +5.6% to target, rec 2.57.

RAISED its FY2027 outlook on 9 Sep - the only positive-revision name in the section. Rev +13.7%, EPS +40.7%, fwd P/E 14.5, FCF yield 4.6%, div 3.1%, ND/EBITDA ~2.7x, +13.2% to $104.76. Op margin 19.3% / ROE 10.6% is the quality brake.

Best managed-care risk profile: Cigna EXITED Medicare Advantage, the business hurting UNH and HUM. Fwd P/E 8.2 / PEG 0.77 and a 11.0% FCF yield (the highest in the section), rev +6.7%, EPS +10.2%, +23.9% to $341.42. PBM reform headline risk is the offset.

Third distributor, verified as an XLV top-25 holding. Highest FCF yield of the three at 8.5%; rev +5.8%, EPS +68.8% as the Medical-segment turnaround lands, ND/EBITDA ~1.7x. Fwd P/E 17.0 / PEG 1.24 and +13.2% to $270.94 on a strong-buy 1.50.

⚠ caution: FY2026 guidance cut in August, sustained negative estimate revisions

Roster gap: animal health. Genuinely high quality (op margin 40.7%, ROE 64.9%, ND/EBITDA ~1.9x) at a fwd P/E of 11.3 with a 6.6% FCF yield after a 52% collapse to the 52wk low. But rev -0.2%, US revenue -7%, companion-animal -11% and FY26 guidance cut: pet spend is the discretionary line a squeezed household cuts, so D stays low despite +30.3% to $96.

Rev +5.1%, FCF yield 4.2%, fwd P/E 15.5 (trailing 118x is charge-distorted). Keytruda 2028 LOE is the structural overhang; +1.6% to $150 consensus after a run from $77.58, so the upside facet of D is spent.

Op margin 34.4%, ROE 46.6%, FCF yield 6.1%, div 3.9%, fwd P/E 9.9. Rev back to +5.7% but Eliquis/Opdivo LOE from 2028; consensus rec 2.46 and only +2.4% to $66.21 after a rally from $42.52.

Rev +13.0% flattered by consolidating Exact Sciences (deal closed 23 Mar 2026, ~$23bn); GAAP EPS -47.5% and op margin 14.7% are depressed by acquisition accounting, and ND rose to ~$27bn (~2.9x). Fwd P/E 17.4, div 2.4%, +13.8% to $120.21.

Distribution peer to MCK: rev +5.1%, EPS +11.9%, ROE 96.9%, fwd P/E 16.4 / PEG 0.69, +13.6% to $369.31. Carries more leverage than McKesson at ND/EBITDA ~3.2x after the MSO/OneOncology deals. Same inflation-passthrough driver.

⚠ caution: revenue -9.8% and EPS -31.8%; clean-earnings screen applied - net margin 58.4% far exceeds op margin 39.2%

Canadian lane. Op margin 39.2%, ROE 23.5%, net cash, FCF yield 5.3% and +39.1% to C$19.95. Scored V and G on OPERATING earnings: reported net margin of 58.4% versus a 39.2% operating margin means the 9.25x trailing P/E is flattered by non-operating items - fwd 12.6x is the honest lens. Revenue is declining.

⚠ caution: 8 Sep cyberattack - company flags material impact, unlikely to meet Q3/FY guidance

Restaged Established (7.5% growth, $65.6bn cap). Disclosed 8 Sep that a cyber incident will have a material impact and it is unlikely to meet FY guidance; sits at the 52wk low, -58% from high. Fwd P/E 13.2 / PEG 0.66 looks cheap but the earnings base is about to be cut.

⚠ caution: patent-cliff overhang and priced through the consensus mean

Rev +9.5%, EPS +64.9%, op margin 35.5%; but ND/EBITDA ~3.2x (D/E 490%) post-Horizon and the stock trades $2 ABOVE the $388.72 consensus mean with a hold rating (2.53). MariTide obesity data is the only re-rating lever.

Verified live and trading. Pre-revenue: $917m cash vs ~$560m/yr implied burn = ~19mo runway (below the 24mo bar for a Phase 3 obesity programme). Licensed Hengrui asset rather than proprietary discovery; at the 52wk low ($15.15), -46% from high, but +179% to $42.40 on 5 analysts.

⚠ caution: revenue -76.3% YoY as partnership/milestone revenue collapsed

Net cash ~$404m ($540m cash vs $136m debt) funds runway past 2028 (>24mo) — but TTM revenue is -76.3% versus the +96% that drove July's score. Thesis has shifted to the internal pipeline (ABCL635 obesity/VMS, ABCL575); +52.8% to $17.13, rec 1.11, FMP rating C-.

Rev +10.5%, op margin 18.8%, ND/EBITDA ~3.5x; fwd P/E 22.0 / PEG 1.83 and only +5.4% to $638.11 after a rally from $435.27. D is held down deliberately: tools revenue is levered to pharma/biotech R&D capex, the line cut first in a stagflation squeeze.

Roster gap: hospitals. Rev +8.7%, op margin 15.2% (best-in-class operator), relentless buybacks - but structurally levered by design at ND/EBITDA ~3.5x with negative book equity. Fwd P/E 13.2 and only +7.0% to $451.48, rec 2.00. D scored down for nursing wage inflation, uncompensated care and the ACA subsidy cliff.

⚠ caution: FMP rating D+ and priced to consensus (+2.9% to target)

Rev +21.5% on clonoSEQ MRD volume and FCF has turned positive (+$19m TTM) - a real turnaround. But net debt $66m, op margin -22%, FMP rating D+, and at $24.37 versus a $25.07 mean target the upside facet of D is gone after a 2x run off $12.00.

Rev only +5.5% with the bioprocessing destocking hangover still unwound; op margin 19.8%, ROE 7.6%, ND/EBITDA ~3.4x. Fwd P/E 22.1 / PEG 1.24 and +11.7% to $229.09 on a strong-buy 1.50. Same R&D-capex driver headwind as TMO.

Canadian lane. Rev +34.3% from the LatAm specialty-pharma roll-up, net cash C$87m, D/E 4.3%, FCF yield ~6.5%, beta 0.04. Profitability is the problem: op margin 6.2%, ROE 1.9%, trailing P/E 65.9. Near the 52wk high after nearly doubling; +13.2% to C$11.19 on 7 analysts.

Roster gap: orthopaedics. Statistically cheap - fwd P/E 10.4 (FY27 consensus EPS 9.07 confirmed), PEG 0.62, FCF yield 6.0%. But rev only +4.8%, op margin 18.0%, ROE 6.4%, ND/EBITDA ~3.1x, and knees/hips are the most deferrable elective procedures in the sector.

Roster gap: diagnostics majors. Rev +5.8%, EPS +28.2%, fwd P/E 16.1 / PEG 1.28, ND/EBITDA ~2.9x, +6.8% to $341.50 with the stock near its 52wk high. Op margin 12.2% is structurally thin and PAMA reimbursement plus wage inflation are the stagflation squeeze.

Canadian lane, the most investable TSX health-care name found: C$2.95bn cap, 9 analysts, +28.5% to C$39.83. Rev +59.4% on the Revera/LTC acquisitions, ND/EBITDA ~2.8x. Government-funded, inflation-indexed LTC revenue is a real stagflation defence, but gross margin 14.5%, current ratio 0.75 and nursing wage inflation cap it.

Cheapest large pharma on cash: FCF yield 7.9%, div 6.2%, fwd P/E 9.6. But rev only +2.6% into the 2026-28 LOE cliff, ROE 5.0%, and +2.5% to $28.61 consensus with the stock near its 52wk high.

Canadian lane. Pre-revenue: C$26.1m cash vs ~C$15.5m/yr burn = ~20mo runway, and a Phase 3 needs more — financing required. CardiolRx Phase 3 MAVERIC (recurrent pericarditis) is the dated catalyst; at the 52wk high, +92% to C$6.00 but only 2 analysts, so Low confidence caps at Interest.

⚠ caution: leverage ~3.8x ND/EBITDA (D/E 258%) - below the 4x line, which is itself only a caution threshold under the revised rule

Rev +8.7% but EPS -0.6% and op margin 13.0%; net debt ~$14.2bn on ~$3.7bn EBITDA. Fwd P/E 17.7 / PEG 0.97 with a strong-buy 1.43, yet only +8.0% to $276.28 after a 66% run off $154.50. CRO demand is clinical-trial spend - rate-starved biotech funding is the driver headwind.

⚠ caution: DOJ investigation and medical-cost-trend overhang

Rev has stalled at +0.4% and op margin has fallen to 7.1%; leadership churn plus a live DOJ probe. FCF yield 6.9% and fwd P/E 17.5 / PEG 1.08 with +21.0% to $475.23 after a rally off $255.97. D is scored DOWN: medical cost trend inflation is running ahead of premium repricing.

⚠ caution: leverage ~4x ND/EBITDA ($62.3bn net debt)

Roster gap: pharmacy/PBM. Fwd P/E 11.2, FCF yield 6.6%, div 2.8%, +21.6% to $116.04 on a strong-buy 1.44. But op margin 3.9%, ROE 6.2% and ~$62.3bn of net debt (~4x, at the hard-gate boundary though interest cover is ~5x). Aetna cost trend versus inflation-passthrough pharmacy volume roughly offset in D.

⚠ caution: sustained negative estimate revisions

Rev +1.4% and EPS -13.1%; op margin 4.6%, ROE 11.1%. Cheap on fwd P/E 13.5 with a 5.0% FCF yield and +12.7% to $449.10, but Medicaid redeterminations and ACA risk-pool deterioration keep estimates falling - the worst managed-care driver in the section.

⚠ caution: net-debt/EBITDA ~6.5x is above the 4x line and the coverage basis is UNRESOLVABLE — the provider's interest-expense field is zero, so neither EBIT-cover nor EBITDA-cover can be struck. Both limitations stated; capped at Interest rather than either cleared or hard-gated.

Canadian lane, the most plausible TSX candidate - and it fails on merit. Gross margin 57.2% and rev +9.1%, but TTM interest coverage is 0.96x, net debt ~$4.8bn on ~$0.74bn EBITDA (~6.5x), net margin -3.2% and tangible book -$4.05/sh. BHC still owns ~88%; 1 analyst covers the TSX line at ~flat.

⚠ caution: net-debt/EBITDA ~4.7-5.0x is above the 4x line and the coverage basis is UNRESOLVABLE — the provider's interest-expense field is zero, so neither EBIT-cover nor EBITDA-cover can be struck. Both limitations stated, and the caution caps rather than clears — though it is the Fit of 44, below the 45 line, that sets this row's verdict, not the gate.

Rev +12.7% and op margin 27.2% do not rescue the capital structure: EV C$23.2bn against a C$3.25bn market cap means ~C$20bn of net debt on ~C$4bn EBITDA. Xifaxan LOE from 2028, the BLCO separation still undelivered, no analyst target on the TSX line.

⛔ hard: delisted/unresolvable - acquired by Abbott, deal closed 2026-03-23

DELISTED. Abbott completed its ~$23bn acquisition of Exact Sciences on 23 Mar 2026; FMP profile returns isActivelyTrading=false and Yahoo has no quote. Not a live security - remove from the universe. Cologuard/Oncotype exposure now sits inside ABT.

Q2 rev +36% YoY, EPS +88%, GM 67.7%; net margin 50.4%, ROE 34.6%, PEG 0.54; +32% to consensus. Best fundamentals in the section, but macro rates its sector a headwind (XLK U/U/U, QQQ SU/U/N) and Taiwan imports ~98% of its energy - $100 Brent lifts fab power costs.

ⓘ note: reported EPS -19% YoY is depressed by non-operating investment losses - G and Q scored on operating income (+33% YoY)

Rev +7.6% but operating income +33% YoY, GM 70.5% expanding; net margin 27.9%, ROE 18.9%, P/E 15.5, P/FCF 10.0, net cash ~= book. China games are the most defensive China consumer line in a squeezed economy - domestic, low-ticket, no imported-input cost.

ⓘ note: the debt-service and leverage limbs are INAPPLICABLE BY RULE (section 4a lender clause) — not passed and not waived. For a deposit-taking bank or consumer lender, interest expense is a revenue-generating input rather than the cost of financing an asset base, so EBIT/EBITDA cover is undefined rather than weak; TTM net interest income is positive. Judged instead on capital adequacy, credit quality and reserve coverage, and scored on NET revenue rather than the provider's gross interest income. Stated limitation: section 4a sets no numeric capital thresholds yet, so the only surviving quantitative credit gate here is the Distress limb (multiple D-F ratings or going-concern language). NU: $15.17bn cash against $5.90bn debt — net cash — and +$2.84bn net interest income in Q2'26.

Q2 net income +66% YoY, EPS +69%, NII +35%; ROE 27.2%, PEG 0.38. Brazil is an energy exporter so terms of trade and the BRL are supported, and a high Selic fattens NIM; only +5% to consensus is the check on it.

Q2 rev +8.1% YoY but EPS -11.4%; net margin 20.4%, ROE 20.6%, GM 57.3% and rising; P/E 7.9, P/FCF 6.7 on ~CNY456bn net cash. China consumer squeezed by $100 Brent (largest energy importer) but PDD is the trade-down winner; Cons Disc SU near term, EM long O.

ⓘ note: the section 4a lender clause does NOT apply here — a payments or platform business finances itself like any corporate, so the ordinary debt-service and leverage limbs apply in full.

July's caution gate is cleared: Q2 net income +28% YoY (was flat/-10%) on rev +55.8% and accelerating; ROE 37.7%, PEG 0.61, net cash, diluted share count -3.2%. GM 38.6% -> 31.8% is the take-rate watch item. Cross-border EM payments straddle exporters and importers; FX volatility widens spread income.

Q2 rev +59.8% YoY, EPS +125%, GM 47.6% -> 58.0% as $100 Brent flows straight through; P/E 4.8, EV/EBITDA 4.0, 7.5% yield. The clearest energy-exporter beneficiary in the section (Oil SO/O/U, XLE O/O/O, BRL terms-of-trade support); state control is the discount, and only +6% to a stale consensus.

The largest EM index constituent alongside TSMC and had no row in this section: net margin 29.8%, ROE 19.2%, GM 56.2%, P/E 14.4, EV/EBITDA 10.7, rising dividend and shrinking share count. Trading near the 52-week low ($54.68 vs $52.84-87.68). Games/social/fintech is domestic and low-ticket - the most energy-shock-resistant China exposure.

Q2 rev +48.1% YoY and accelerating, operating income +28%, GM 45.6% stable; P/E 40 / PEG 1.23; +36% to consensus. SE Asia is net energy-importing (Indonesia, Philippines, Thailand) so fuel/logistics costs and the consumer are squeezed near term; long-run EM O and a weak USD are the offset.

ⓘ note: the debt-service and leverage limbs are INAPPLICABLE BY RULE (section 4a lender clause) — not passed and not waived. For a deposit-taking bank or consumer lender, interest expense is a revenue-generating input rather than the cost of financing an asset base, so EBIT/EBITDA cover is undefined rather than weak; TTM net interest income is positive. Judged instead on capital adequacy, credit quality and reserve coverage, and scored on NET revenue rather than the provider's gross interest income. Stated limitation: section 4a sets no numeric capital thresholds yet, so the only surviving quantitative credit gate here is the Distress limb (multiple D-F ratings or going-concern language).

Scored on net revenue not FMP gross interest income: ROE ~17%, GNPA <2%, P/E 17.7 / P/B 2.6, +23% to consensus. Downgraded on D: India imports ~85% of its oil, so $100 Brent means a wider CAD, weaker INR and an RBI forced to hold or hike - a direct headwind that the July soft-landing score did not carry.

ⓘ note: the debt-service and leverage limbs are INAPPLICABLE BY RULE (section 4a lender clause) — not passed and not waived. For a deposit-taking bank or consumer lender, interest expense is a revenue-generating input rather than the cost of financing an asset base, so EBIT/EBITDA cover is undefined rather than weak; TTM net interest income is positive. Judged instead on capital adequacy, credit quality and reserve coverage, and scored on NET revenue rather than the provider's gross interest income. Stated limitation: section 4a sets no numeric capital thresholds yet, so the only surviving quantitative credit gate here is the Distress limb (multiple D-F ratings or going-concern language).

Net-revenue basis: ROE 12.6% post-merger, P/E 13.4 / P/B 1.75, fwd PEG 0.81, 2.3% yield, +36% to consensus. Same India energy-importer drag as IBN; deposit repricing still normalising.

Brazil staples had no candidate. ROE 18.3%, GM 50.1%, net cash (D/E 0.03), interest cover 24x, 10% FCF yield and a 4.2% dividend at P/E 15.0. Defensive inside an exporter economy whose terms of trade improve at $100 Brent; only +6% to consensus and fwd PEG 2.9 cap it.

Q2 rev +49.8% YoY (accelerating) but EPS -10.9% and GM 45.6% -> 40.9% on credit provisions and logistics spend; P/E 51 and only +9% to consensus. Best geography mix in the section - Brazil and Argentina are energy exporters and terms-of-trade winners - but the price already reflects it.

⚠ caution: sustained negative estimate revisions / Hold consensus - only +5.0% to consensus target

P/E 13.3 and 4.6% yield look cheap but fwd PEG 3.0 says growth is ~nil; ROE 34.5%, net cash, FCF conversion 93%. Indian IT sells discretionary US/EU tech budgets - exactly what XLK U/U/U and US Equities U/U/U cut first.

ⓘ note: the debt-service and leverage limbs are INAPPLICABLE BY RULE (section 4a lender clause) — not passed and not waived. For a deposit-taking bank or consumer lender, interest expense is a revenue-generating input rather than the cost of financing an asset base, so EBIT/EBITDA cover is undefined rather than weak; TTM net interest income is positive. Judged instead on capital adequacy, credit quality and reserve coverage, and scored on NET revenue rather than the provider's gross interest income. Stated limitation: section 4a sets no numeric capital thresholds yet, so the only surviving quantitative credit gate here is the Distress limb (multiple D-F ratings or going-concern language). XP: a broker-dealer with banking operations, which qualifies on the same clause.

P/E 9.6, P/B 2.04, fwd PEG 0.69, ROE 21.4%, net margin 27.6%; +23% to consensus. High Brazilian rates keep fixed-income flows and NII fat even as equity issuance stays shut; 16x financial leverage is broker-normal but caps H.

China consumer had no restaurant/staples candidate. P/E 15.5, EV/EBITDA 8.6, 6.4% FCF yield, net cash (debt/market cap 0.004), ROE 16.1% and a share count shrinking ~5%/yr. Near the 52-week low at $42.63 - the China consumer squeeze under Cons Disc SU is the whole reason it is cheap.

⚠ caution: ~49% of TTM net income is non-operating (Q3-25 one-off gain) - V and G scored on operating earnings (~13x, not the headline 5.6x)

Latest filed quarter is Q1-26: rev +16.5%, operating income +10%; GM 80.3% but operating margin 24.9% vs 48.7% reported net margin. Jet fuel at $100 Brent raises airfares and Cons Disc is SU - travel demand is a headwind, not the July tailwind.

ⓘ note: the debt-service and leverage limbs are INAPPLICABLE BY RULE (section 4a lender clause) — not passed and not waived. For a deposit-taking bank or consumer lender, interest expense is a revenue-generating input rather than the cost of financing an asset base, so EBIT/EBITDA cover is undefined rather than weak; TTM net interest income is positive. Judged instead on capital adequacy, credit quality and reserve coverage, and scored on NET revenue rather than the provider's gross interest income. Stated limitation: section 4a sets no numeric capital thresholds yet, so the only surviving quantitative credit gate here is the Distress limb (multiple D-F ratings or going-concern language). ITUB: TTM net interest income R$61.0bn (17,194 + 7,399 + 14,710 + 21,704m BRL), comfortably positive.

⚠ caution: price $8.31 is above the highest analyst target $7.77 (-23% to the $6.38 consensus)

Best-in-class Brazilian bank - ROE 20.5%, P/E 9.8, 7.6% dividend yield - but the price has run past every published target. Brazil's exporter terms-of-trade support and fat Selic NII are already in it.

ⓘ note: the debt-service and leverage limbs are INAPPLICABLE BY RULE (section 4a lender clause) — not passed and not waived. For a deposit-taking bank or consumer lender, interest expense is a revenue-generating input rather than the cost of financing an asset base, so EBIT/EBITDA cover is undefined rather than weak; TTM net interest income is positive. Judged instead on capital adequacy, credit quality and reserve coverage, and scored on NET revenue rather than the provider's gross interest income. Stated limitation: section 4a sets no numeric capital thresholds yet, so the only surviving quantitative credit gate here is the Distress limb (multiple D-F ratings or going-concern language).

Korea had no candidate in this section. P/E 10.0, P/B 1.01, 4.8% yield, and the value-up buyback/payout programme has taken the stock from $77 to $127; ROE 10.1% is the quality limiter. Won weakness and Korea's energy-import bill offset the higher-for-longer NIM tailwind.

⚠ caution: price $14.59 is above the sole covering analyst's $12.00 target (n=1, thin coverage)

Middle East/Africa had no candidate. Coal- and gas-to-liquids with a rand cost base and USD-linked fuel revenue - the purest $100-Brent beneficiary here: +178% off the low to $14.59, EV/EBITDA 3.4, P/B 0.92, net debt/EBITDA ~1.2x. Through-cycle quality is poor (net margin 4.5%, ROE 7.1%, no dividend).

⚠ caution: Q2 net income $252m vs $19m operating income (interest income + tax benefit) - V and G scored on operating

ⓘ note: the section 4a lender clause does NOT apply here — a payments or platform business finances itself like any corporate, so the ordinary debt-service and leverage limbs apply in full.

Q2 rev +21.7% YoY (steady, not accelerating), GM 43.6% flat, ~47% of the market cap in cash; +83% to consensus. Downgraded on D: ride-hailing and delivery are the most fuel-sensitive business models in the section and every core SE-Asian market is a net energy importer.

⚠ caution: net income exceeds pretax income (effective tax rate -35.6%) - the 3.9x headline P/E is tax-benefit flattered

ⓘ note: the section 4a lender clause does NOT apply here — a payments or platform business finances itself like any corporate, so the ordinary debt-service and leverage limbs apply in full.

GM 72.4%, ROE 36.7%, EV/EBITDA 3.2, P/B 1.40 and a very large capital return; interest coverage 2.48x is the thin spot. Brazil exporter tailwind, but a Selic that now stays high squeezes SMB credit and card volumes.

Mexico airports. Net margin 26.0%, ROE 20.5%, EV/EBITDA 7.8, P/E 12.9 and a 9.4% yield - but at the 52-week low ($253.88 vs $249.58-381.52) with traffic falling and a payout above 100% of earnings. Jet fuel at $100 Brent raises fares into leisure destinations exactly as Cons Disc goes SU.

Symbol change: the NYSE ADR now trades as EMBJ; ERJ is the retired line (same CIK 1355444 / ISIN US29082A1079) and still returns frozen data, which is what produced last run's false hard gate. Live: $74.42, revenue +10.4%, earnings +113.9%, forward EPS $3.97 vs $2.47 trailing, operating margin 13.0%, ROE 12.2%, net debt ~$2.5bn against $11.2bn cash, FCF +$1.67bn, interest cover 3.06x. Forward P/E 18.7 and +23% to a $91.60 mean target across 15 analysts (strong-buy 1.47). Brazil is an energy exporter, which helps on the EM axis, but the driver is split: commercial-aero demand pays $100 jet fuel while the defence half gets the rearmament tailwind (Defense O/O/SO).

⚠ caution: sustained negative revisions - fwd PEG 3.58 and the stock is at its 52-week low ($1.68 vs $1.68-3.09)

INFY's direct peer. ROE 17.0%, net margin 13.9%, net cash, 4.8% yield at P/E 13.2 - but earnings are declining and the discretionary US/EU tech budget it sells into is what stagflation cuts first. Weaker franchise than INFY on the same headwind.

Net margin 3.6%, ROE 10.4%, payout 172% of earnings; P/E 19.6, 6.9% yield, +16% to consensus. OXXO's fuel and convenience mix passes through higher pump prices, but Mexico imports refined product and Staples are U/U/U.

Surfaced by get_related_tickers on MELI. Revenue compounding ~+20% at P/S 0.75 after a 57% drawdown ($14.81 vs $14.48-34.08), but TTM net margin -2.2% as Developing Offerings and Farfetch drag; +70% to consensus. Korea is a net energy importer.

Taiwan ex-TSMC. Advanced-packaging boom has taken it from $10.93 to $40.64 with PEG 0.60, but P/E 46, P/B 7.2 and negative FCF on capex; GM 19.5% and net margin 8.5% are OSAT-commodity, not foundry. Same XLK U/U/U and Taiwan energy-import headwind as TSM without the margin buffer.

Q2 revenue -3.2% YoY but recovering off the Q4-25 food-delivery trough (gross profit was negative that quarter); GM back up to 17.0%, EPS +21%, share count -9.3% on buybacks. P/S 0.19 and P/B 1.12 with 12.8% FCF yield; TTM net margin is still only 1.1%.

Now loss-making: TTM net margin -3.8%, operating margin -6.0% as ad revenue shrinks. P/B 0.79 (below book) with cash CNY490/share vs CNY869 book is the whole case; runway is years so no burn gate. Ad spend is the first cut in a squeezed China consumer.

⚠ caution: revenue decelerating (+8.3% YoY) while gross margin declines 44.9% -> 38.0% - both together

Jun-26 quarter: rev +8.3% but operating income -45%, EPS -80%, FCF -CNY33.7/share on AI capex plus the instant-commerce subsidy war. Reported P/E 24.3 on collapsing earnings is not the July value case; China is the largest energy importer and Cons Disc is SU.

⛔ hard: debt service impaired on both bases — EBIT-cover 1.23x and EBITDA-cover 1.65x, against 1.5x and 3.0x — with negative shareholders' equity (-$3.42/share, debt/assets 0.96).

Convertible-funded buybacks have left negative book equity and 1.23x interest cover - a hard gate regardless of the +43% to consensus. P/E 139 on a 3.2% net margin; India travel also faces $100-Brent airfares.

Mexico industrials/materials had no candidate. P/B 1.27 and 9.8% FCF yield against a 2.8% net margin and 3.75% ROE; P/E 32.7. Materials are O/O/O, but cement kilns are the most fuel-intensive process in the section - $100 Brent is a direct cost line, not a tailwind.

China EV had no candidate. Now loss-making: TTM net margin -4.4%, GM 13.6% in the price war, FCF -CNY15/share. Net cash (CNY85/share vs a CNY65 book) and P/B 1.24 give a long runway so no burn gate, but at $12.02 against a $11.65-27.10 range there is no evidence the derating is over.

The section's supply-shock beneficiary: rev +346% YoY, gross margin 72.6%, net margin 55.9%, ROE 67%. Fwd P/E 6.6 vs trailing 23.1; +48% to consensus $1,513 on 45 analysts (strong buy). Net cash $19.6bn, interest coverage 258x. Q and V held back deliberately - forward PEG 2.46 says peak-cycle memory earnings, not a durable margin. D is the section's second-highest on the DRAM/HBM shortage, an idiosyncratic driver that survives Tech U/U/U.

Rev +106% YoY and accelerating; op margin 65.2%, net cash ~$60bn, interest coverage 427x. CLEAN-EARNINGS FLAG: non-operating income $32.2bn = 16.7% of TTM net income, so V/G scored off operating earnings - clean EPS ~$6.83 vs reported $7.97, P/E ~33 not 28. At $225 the stock sits BELOW the lowest analyst target ($270); +53% to consensus $345. D 55: contracted backlog is the funded-order-book exception, but hyperscaler capex is the line most at risk in an energy-shock stagflation.

Rev +52.8%, op margin 77.7%, gross margin 88.5%, FCF/OCF 99%. De-rated 59% from the 52wk high ($307.60 vs $745.61) to fwd P/E 14.7 / PEG 0.69, so V flips from a drag to a support; +65% to consensus $508. GICS note: now classified Comm Services (advertising), kept in Technology for continuity. D 53 - mobile ad budgets are discretionary into a squeezed consumer, offset by the size of the discount.

The defensive recurring-revenue compounder of the section: beta 0.70, vertical-market software, ROE 23.3%, FCF C$2.79bn. Down 39% from the 52wk high to fwd P/E 15.4 / PEG 0.60; +40% to consensus C$3,923. M 92 on Leonard's capital-allocation record. D 58 - stickiness and low beta offset Tech U/U/U, but a serial acquirer's cost of capital rises with a hike-vs-hold Fed.

Rev +85.5%, net margin 42.9%, FCF $30.5bn, FCF/OCF 97%. Fwd P/E 18.8, PEG 0.35; +46% to consensus $533 (strong buy, 46 analysts). Net debt $35.4bn, interest coverage 14.2x, tangible book negative on goodwill. D 59 - custom AI-accelerator orders are largely booked and funded, the exception the sector headwind does not erase.

New this run - memory sub-industry, the NAND counterpart to Micron. Rev +372%, op margin 78.5%, net cash $4.6bn, FCF $7.7bn. Fwd P/E 6.7 vs trailing 24.0; +20% to consensus $2,125. Q and V held down on purpose: 78% op margins are shortage rent, and NAND is the worst through-cycle margin structure in semis. Confidence Medium - only ~18 months of standalone history since the WDC spin.

New this run - the electronic-components/connectors sub-industry had no candidate. Rev +55%, op margin 29.8%, ROE 38.1%; net debt/EBITDA ~1.4x. AI-datacentre interconnect content plus defense/aerospace exposure (XAR O/O/SO) is a genuine dual offset to Tech U/U/U. Fwd P/E 25.0, PEG 0.94, +22% to consensus $99.

Rev +24.8%, op margin 33.7%, ROE 41.1%, net cash $1.9bn. July's 'px approximately consensus' caution gate is spent - now +37% to consensus $641 (strong buy, 35 analysts) after a 37% drawdown. D 57 on the memory-led WFE capex upcycle, the section's best-funded order driver; China export-control risk is the offset.

FY26 rev $331.8bn +17.8%, op margin 46.8%, ROE 30%; but FCF/OCF conversion down to 37% as AI capex eats cash (P/FCF 55). Fwd P/E 27.4, PEG 0.87. Non-operating income 8% of FY26 net (incl. a $9.97bn Q2 equity-stake gain) - below the 15% clean-earnings screen but noted. Only +12% to consensus $553. D cut hard: Tech U/U/U and QQQ SU/U/N; defensive recurring revenue is the offset, the capex bill is not.

Rev +48.5%, op margin 43.07% - extraordinary for HDD and pure nearline-shortage pricing power. Fwd P/E 16.3, PEG 0.49, +24% to consensus $1,125 (strong buy). July's 'priced to consensus (+2%)' caution gate no longer applies. H 66 is the drag: net debt $2.2bn on a thin equity base (D/E 180%), beta 2.09. Supply-shock beneficiary, so D clears the sector headwind.

New this run - semicap equipment sub-industry. Rev +30%, op margin 37.4%, ROE 65.1%, net cash $1.5bn. The most memory-levered WFE name, so it inherits the DRAM/NAND shortage driver directly. V 52 is the brake: P/S 17.0, fwd P/E 27.0, PEG 1.43. +18% to consensus $371.

Rev +92.8% YoY and accelerating, gross margin 84.8%, op margin 42.8%, Rule of 40 approximately 136, net cash, no debt. V 15 - EV/Rev approximately 63x, diluted P/E 144, EV/EBITDA 126, the most duration-exposed multiple in the section into a hike-vs-hold Fed. Note the 1.4% effective tax rate flattering EPS, and non-operating income at 14.5% of net income (just under the clean-earnings screen). No gate: hyper-growth clears the EV/Rev carve-out and price sits below the $215 high target - but upside to consensus is only +8%.

Halved from the 52wk high ($316.83 vs $705.08) to fwd P/E 11.6, P/FCF 13.5, PEG 1.06, 1.7% yield - V 86 is the thesis. ROE 23.6%, op margin 17.6%, FCF $6.4bn. G 52 / C 45 are the brakes: rev +13.7% and EPS flat -0.8%. D 49 - recurring tax/accounting revenue is defensive, but QuickBooks is SMB-cyclical into a squeezed household; +28% to consensus $406.

⚠ caution: valuation extreme (EV/Rev ~22x with 37.7% growth, below the hyper-growth carve-out)

Rev +37.7%, op margin 45.4%, ROE 31.5%, zero debt and $13.3bn cash - the cleanest balance sheet in the section. But EV/Rev approximately 22x on sub-40% growth trips the valuation-extreme caution gate again (P/E 61.2, P/S 23.1), capping at Interest. +25% to consensus $241.

Clean-earnings screen, corrected: TTM other income $5,397m against net income $9,424m = 57.3% non-operating (the prior ~40% set a TTM net margin against a quarter-basis operating margin; FMP's TTM operating margin is 34.9%, not 43.6%). So the headline 18.1x P/E is ~39-43x on after-tax operating earnings, and V is scored there. Net cash $388m, +36% to target. The NAND/HDD supply-shock driver is intact and is what earns its D.

Rev +37%, op income inflecting (earnings +423%), ROE 22.4%. EV/Rev only 8.2x - the cheapest AI-interconnect exposure in the section; fwd P/E 29.4, PEG 0.55, +48% to consensus $504. Q 66 reflects 44% hardware gross margins. D 58 on funded optical/coherent build-out for AI datacentres.

New this run - XIT's #3 holding (23.6%) and the largest Canadian gap in the July list. Rev +62.4%, earnings +74.2%, fwd P/E 17.4 / PEG 1.00 / P/S 3.78 - the cheapest AI-hardware exposure here. +43% to consensus C$671 (strong buy). Q 62 is honest: 9.8% op margins are structural for an EMS, and hyperscaler customer concentration is the risk. Confidence Medium - only 5 analysts on the .TO line.

New this run - hardware/networking sub-industry. Rev +17.6% is Cisco's best in a decade; op margin 27.7%, ROE 27.3%, FCF $11.2bn, beta 0.99, 1.5% yield. Fwd P/E 19.5, PEG 1.01, +26% to consensus $138. D 49 - AI-ethernet orders and a defensive subscription base only partly offset the fact that campus/enterprise networking is a discretionary IT-capex line.

New this run - analog & power semis sub-industry (TXN was the only prior candidate). Rev +39.6%, op margin 39.5%, fwd P/E 22.3, PEG 0.54, +29% to consensus $470 (strong buy). Q 78 not higher: ROE is only 12.2% on the Maxim goodwill. D 49 - the analog upcycle is real but its end markets are auto and industrial, which the regime rates weak-to-neutral.

New this run - semicap equipment. Best-in-class process control: op margin 42.5%, ROE 87.5%. But rev +15.2% is half LRCX's and PEG 1.77 / P/S 17.5 leave little room; +29% to consensus $234 after a 41% drawdown. Least memory-levered of the three semicap names, so the lowest D of the trio.

Rev +104.5% with earnings +186%; net cash $1.2bn, no debt. V 25 - P/S 43.4x and P/E 149 are the section's second-richest sales multiple; no gate only because 104% growth clears the hyper-growth carve-out. Beta 3.78, down 40% from the high, +30% to consensus $390. D 53: real AI-rack connectivity content, but tied to hyperscaler build timing rather than a contracted backlog.

Fwd P/E 15.4, P/FCF 11.5, PEG 1.05 on $17.7bn FCF - V 84. Op margin 21.4%, ROE 19.4%, net debt $31.0bn comfortably covered. G 48: rev +10.8% and decelerating. D 40 - near the 52wk high with only +10.7% to consensus, seat-based enterprise SaaS is squeezed both by IT-budget cuts and by AI-agent substitution of the seat model itself.

The cheapest high-quality software name here: P/E 14.7, fwd 9.4, P/FCF 11.1, PEG 0.65, op margin 35.3%, FCF $9.2bn. And the market is right to discount it - consensus is HOLD (2.73), rev +12.7% decelerating, only +7.6% to the $277 target. D 35: creative and marketing budgets are cyclical, and generative AI attacks the product itself. A value case, not yet a signal.

New this run - cybersecurity sub-industry, and the profitable one: GAAP op margin 33.6% against PANW's 5.0% and CRWD's -2.3%. Rev +25.6%, net cash $3.5bn, ROE 117%, founder-led. EV/Rev 14.9x so no gate. C 36 and D 41 are what hold it under the bar - Hold consensus and only +3.0% to the $162 target.

Beta 0.198, net cash C$369m, op margin 32.9%, rev +14.7%. The driver is genuinely counter-cyclical here - customs/trade-compliance software demand rises with tariff and deglobalisation complexity. But fwd P/E 22.9 / PEG 1.67 / P/S 11.5 is not cheap and yfinance returns no .TO consensus target, so C is capped. Falls from July's Watchlist to Interest on the arithmetic - and note the July row was itself off-rule, scoring in the mid-60s yet carrying a Watchlist verdict where section 4b maps that band to Interest.

New this run - XIT holding, application software. Rev +16.4%, op margin 15.4%, ROE 20.7%, net cash C$266m, beta 0.751; +26% to consensus C$208. Like Descartes the driver runs counter to the regime - supply-chain disruption and tariff complexity drive demand for planning software. Rule of 40 near 36 is the brake on Q.

New this run - IT services & consulting. P/E 14.2, fwd 12.1, P/FCF 9.0, 3.5% yield, net cash, FCF $12.1bn - statistically the cheapest quality name here. But rev is +5.6% and it is only +3.9% to consensus $184 after a 39% drawdown. D 33 is deliberate: discretionary consulting budgets are the first IT line cut in a stagflation, and generative AI attacks the billable-hour model directly.

Rev +22.8% on the analog recovery, op margin 42.6%, ROE 35.2%. But FCF is only $3.5bn against a 85% dividend payout while fab capex runs hot, and P/E 39.8 / P/S 12.3 is not cheap (PEG 0.92). +24% to consensus $325. D 47 - auto and industrial end markets are weak-to-neutral under this regime.

New this run - XIT's #4 holding (9.5%), IT services. P/E 11.8, fwd 9.7, P/FCF 9.0, P/B 1.9, beta 0.174, FCF C$2.19bn, relentless buybacks. +28% to consensus C$121. But rev is +2.5% and the same consulting-budget headwind as Accenture applies; D 45 gives credit for the defensiveness, not for a driver.

⚠ caution: valuation extreme (EV/Rev ~21x with 36.5% growth, below the hyper-growth carve-out)

Rev +36.5%, custom AI silicon and optical DSP, +21% to consensus $285 (strong buy, 41 analysts). But EV/Rev approximately 21.1x on sub-40% growth trips the valuation-extreme caution gate (P/E 78.3, fwd 35.2). Q 68 - GAAP op margin 16.7% and ROE 16.5% lag the AI-semis cohort. Clean-earnings screen, added at audit: operating margin 16.71% against a pretax 32.37% and net 27.94% means 56.1% of net income arrives below the operating line (EBT/EBIT 1.94) — the same magnitude as Western Digital's 57.3%, and it had received none of the same treatment. On after-tax operating earnings the trailing multiple is roughly 129x, not the headline 78.3x, and V is cut from 40 to 30 on that basis.

CLEAN-EARNINGS FLAG: non-operating income $1.07bn = 16.7% of TTM net income, so V/G off operating earnings - clean P/E ~156 vs headline 133. Rev +50.1% with op income inflecting from -$134m to $1.99bn; net cash $8.8bn. July's EV/Rev caution gate is spent (19.8x now, and 50% growth clears the hyper-growth carve-out). But fwd P/E 33.5 needs a ~4x EPS jump to land, near the 52wk high, only +18% to consensus. Q 66 - op margin 17.3% and ROE 10.2% are half NVDA's.

Rev +24%, FCF $5.1bn (P/FCF 26.4) - the multiple has normalised hard from the 52wk high, fwd P/E 26.3 / PEG 1.02. But GAAP op margin is 4.1% on SBC, earnings growth is -21.9%, and there is only +8.1% to consensus $142. D 40 - enterprise workflow seats are a discretionary IT-budget line. Falls from July's Watchlist to Interest (Fit 65); Donatien-Pick status noted separately.

Rev +33.7%, op margin 17.6%, net cash C$4.8bn, FCF C$1.59bn, +30% to consensus C$230. July's caution gate is spent - EV/Rev is now 17.6x (below 20x) and P/E 86 vs 110. Still V 34 on PEG 2.89 / fwd P/E 52. D 41 is the binding constraint: GMV is levered to discretionary consumer spend, and Cons Disc is SU/SU/SU - the worst signal on the board.

⚠ caution: valuation extreme (EV/Rev ~24x with 34.4% growth, below the hyper-growth carve-out)

Rev +34.4%, FCF $4.5bn (39% FCF margin, Rule of 40 approximately 73), net cash, beta 0.908. But EV/Rev approximately 23.9x on sub-40% growth trips the caution gate again; GAAP op margin is only 5.0% on heavy SBC and M 60 reflects the resulting dilution. +17% to consensus $391.

Clean earnings - non-operating income is 0.8% of TTM net, no distortion. Rev re-accelerating to +16.4%, op margin 32.6%, FCF $108bn, ROE 149%, shares -1.4%/yr. But P/E 35.9 / PEG 2.52 near the 52wk high with only +3.5% to consensus $324 - priced to target. D 33: consumer hardware demand into a squeezed household (Cons Disc SU/SU/SU) plus China and tariff exposure is one of the worst driver reads in the section.

⚠ caution: revenue declining -4.0% with EPS -23% and operating-margin compression

Genuinely cheap - P/E 20.1, fwd 17.3, PEG 0.75, 2.2% yield, FCF $10.2bn, ROE 33.8%. But revenue is -4.0% and EPS -23% as Apple insources the modem, consensus is HOLD (2.56) and there is only +10% to the $194 target. Declining revenue with margin compression trips the caution gate.

⚠ caution: valuation extreme (P/S ~64x on a pre-commercial revenue base)

Rev +287% off a tiny base; $2.12bn cash against $54m debt gives a long runway, which is the whole H score. Op margin -408%. +77% to consensus $69 (strong buy, 12 analysts) after a 54% drawdown. D 50: quantum is the longest-duration, zero-cash-flow asset in the section and therefore the most exposed to a hike-vs-hold Fed - the national-security funding stream is the only offset. Insider/founder-ownership check unavailable this cycle (web search budget exhausted).

⚠ caution: revenue declining -8.4% with margin compression; Hold consensus (3.0)

New this run - XIT holding. Net cash C$261m is 31% of the market cap, 7.9% dividend yield, P/E 11.8, beta 0.349. But revenue is -8.4%, the payout ratio is 91%, and consensus is a flat Hold with +9% to C$17. A declining contact-centre/telecom software base - cheap because it is shrinking. Caution gate caps at Interest.

New this run - XIT holding. Statistically the cheapest name in the section: P/E 8.8, fwd 5.4, P/FCF 5.6, P/B 1.35, 4.8% dividend yield, FCF C$1.36bn. Offsetting that: rev +2.9%, net debt C$5.0bn = approximately 2.7x EBITDA (the hard gate for capital-light software is 3x, so it clears by a hair), M 52 on the value-destructive Micro Focus deal, and only ONE analyst target - confidence Low caps the verdict at Interest.

⛔ hard: earnings-integrity — TTM net margin is +4.5% against an operating margin of -49.3% (operating income -$668.6m on revenue $1,355.1m; FMP's own operatingProfitMarginTTM is -0.4934) — so reported profit is entirely non-operating, not marginally so. The earlier '+3.1% vs -0.2%' reading was wrong by roughly 250x on the operating leg and made an overwhelming call look borderline. One-off in character: the Q1'26 item of +$743.4m is concentrated in a single quarter and net interest income is negative in all four (-8.5/-24.8/-49.5/-95.0m).

ⓘ Sector note: the mitigation is real — V is null under the pre-profit rule, so there is no EPS-derived score for the distortion to inflate, which is the channel the clean-earnings screen exists to block. That argument was taken up in the framework rather than granted in the row: section 4a now states when the limb fires. Section 4a's character clause now settles this explicitly: the limb fires above ~70% only when the income is one-off in character, which this is.

CLEAN-EARNINGS FLAG: reports a +3.1% net margin against a -0.2% OPERATING margin, i.e. essentially all reported profit is non-operating gains on equity stakes. Now treated with the earnings-integrity hard gate, not merely the clean-earnings screen - and as a Speculative row V is null, so there is no EPS-derived score for the distortion to inflate. Rev +454% is real; P/S 45.7x; FCF -$9.6bn against $8.0bn cash and only $2.2bn net debt, so this is a funding-dependence risk, not a leverage-gate one. +18% to consensus $287. GICS note: classified Comm Services, kept here for continuity. Note on precedent: NVDA (16.7%), AMD (16.7%) and WDC (57.3%) are NOT precedent for this row — all three sit inside the 15-70% band the screen does not gate. The only true analogue is CCDS.V, which is the other exception, and both are now gated.

New this run - IT services/hardware. Rev +1.1% and EPS -1.8%; P/E 21.1, fwd 18.1, PEG 2.22, 2.9% yield, beta 0.708, FCF $12.0bn. Net debt $57.2bn = approximately 3.1x EBITDA - below the 4x line (itself only a caution threshold now) but the weakest H among the mega-caps. Priced to consensus at +3.1%. D 37 - mainframe/software recurring revenue is defensive, consulting bookings are not.

⚠ caution: valuation extreme (EV/Rev ~39x with 25.8% growth, below the hyper-growth carve-out)

ⓘ note: earnings-integrity limb examined and found not to bite here. Section 4a enumerates three things — "mark-to-market gains on equity stakes, 'other income,' one-off gains" — so bare "other income" IS on the list; the screen declines to read it literally in this row because the purpose test fails. Its stated rationale is that an inflated EPS makes a dear name look cheap, and the distortion here runs the other way. The income is recurring and economically core rather than a revaluation or a windfall, so it is disclosed rather than gated, and where that boundary sits is now written into section 4a's character clause rather than left open. The profit is recurring interest income on the cash pile against a GAAP operating loss driven by stock-based compensation, with trailing P/E already above 5,000 and V punished to 18 — nothing is being made to look cheap.

EV/Rev approximately 39.1x on +25.8% revenue - the richest sales multiple in the section and comfortably inside the caution gate. Trailing P/E 5,204, fwd 129.7, PEG 6.82, GAAP op margin -2.3%. FCF $2.0bn (37% margin) and $4.2bn net cash are the quality offset. Near the 52wk high with only +11.8% to consensus $233.

Rev +156% on a ~$42m base; $477m cash against $15m debt, roughly 5 years of runway at the current burn. Op margin -215%, P/S 73.3. +54% to consensus $21.33, but on 6 analysts and a short post-de-SPAC record - confidence Low caps at Interest. Founder/insider-ownership check unavailable this cycle.

⚠ caution: leverage at the hard-gate boundary - net debt/EBITDA 3.9-4.2x depending on debt basis; FCF -$24.5bn

FY26 revenue +20.6% and the OCI backlog is real, but the buildout is debt-funded: reported total debt $158-167bn against $31.9bn cash, FCF -$24.5bn, interest expense up from $0.92bn to $1.44bn a quarter. NO HARD GATE, deliberately: net debt/EBITDA computes to 4.22x on the yahoo debt figure but 3.93x on the FMP debt/equity-derived figure, against FY26 EBITDA of $32.1bn (corroborated two ways - quarterly sum and the TTM EBITDA margin of 47.65%), and reported total debt is lease-inclusive and could not be reconciled to the company release this cycle. A gate that turns on an unreconciled 3.9-vs-4.2x call would not survive scrutiny, so the credit risk is carried in H 18 and here instead. Interest coverage is 4.52x, comfortably clear. In a regime rating IG credit SU with the Fed debating a hike, this is still the most credit-exposed name in the section; the stock is already -53% from its high. Fwd P/E 14.9, +47% to consensus $241.

⛔ hard: net-debt/EBITDA ~15x breaches the absolute 8x ceiling ($51.6bn of debt, FCF -$9.1bn). EBITDA-cover of 3.18x does not save it — the ceiling applies regardless of coverage.

STATUS CHANGE - hard gate now fires. Rev +112.5% is the fastest in the section, but total debt is $51.6bn against $5.5bn cash (D/E 1,027%), operating margin is -1.9% and FCF is -$9.1bn. Both leverage tests fail outright. EV $101.1bn against a $52.8bn market cap tells the story. A GPU-leasing balance sheet funded in a market the macro rates IG credit SU / High Yield U is the section's clearest credit risk, whatever the +51% to consensus $144 implies.

Genuinely turned: rev +25.6%, GAAP-profitable, op margin 10.3%, net cash C$130m, FCF C$105m. But P/S 10.9 and fwd P/E 34.3 for a 10% op margin is dear, consensus is Hold (3.0) and it is priced to target at +3.5%. D 37 - QNX rides automotive software content, and autos are weak under Cons Disc SU.

⚠ caution: valuation extreme (P/S ~394x on ~$13m of TTM revenue)

STATUS CHANGE - July's DO-NOT-BUY hard gate is LIFTED, and the dilution leg of it was wrong. Actual weightedAverageShsOut ran 298.3m (Q2 FY25) to 333.2m (Q2 FY26) = +11.7%/yr, well inside the >20% hard-gate threshold. No leverage gate either: $394m cash, $7.7m debt, zero interest expense, and an operating burn near $112m/yr = roughly 3.5 years of runway. What remains is a valuation-extreme caution gate: revenue is $13.4m TTM (+185%, accelerating, gross margin turned positive at 42.6%) against a $5.26bn market cap, i.e. P/S approximately 394x. Also note reported net income is dominated by warrant/earnout mark-to-market swings (-$180m in Q3 FY25, +$59m in Q1 FY26). Down 73% from the high.

⚠ caution: earnings-integrity limb UNRESOLVABLE, not fired. The row previously cited 'positive reported EPS of C$0.13 against a -189% net margin', which cannot both describe one period: the +C$0.13 is a stale yfinance trailing-EPS field, contradicted by the same payload's -189% net margin and by the statements (quarterly EPS -0.24/+0.02/-0.06/-0.06; TTM net income about -C$3.1m). There is no reported profit, so a share OF net income is undefined and the limb's stated harm — an inflated EPS making a dear name look cheap — cannot arise. Section 4a's 'unresolvable basis ⇒ caution, never a cleared gate' governs. Low confidence caps here in any case.

Live and trading on the TSXV at C$1.27 (market cap C$42.8m), but very thin - 2,756 shares traded against a 73k average, and one analyst target. EARNINGS-QUALITY FLAG, corrected at audit: a provider field shows trailing EPS of +C$0.13, but that is stale and contradicted by the same payload's -189% net margin and by the statements (quarterly EPS -0.24/+0.02/-0.06/-0.06; TTM net income about -C$3.1m). There is no reported profit, so the earnings-integrity limb has nothing to measure a non-operating SHARE against and is unresolvable rather than fired. The earlier claim that 'the entire reported profit is non-operating' rested on the stale figure and is withdrawn. Rev +849% off a micro base; net cash approximately C$0.3m. Confidence Low caps this at Interest,. Donatien-Pick, currently Stopped on the watchlist.

STATUS CHANGE - July's hard gate ('SELL / weak execution + margin collapse') is lifted. Revenue is +25.4%, operating margin is back to +12.2%, FCF is +$4.9bn, net debt/EBITDA approximately 1.2x and interest coverage approximately 4.7x, so no hard gate now fires. But the stock is up 4.4x off the 52wk low to P/B 6.1 and fwd P/E 51.9 with only +9.4% to consensus $116 - the value case that made it interesting is gone. Q 44 on a still-negative net margin.

⛔ hard: debt service impaired on BOTH bases required by the revised test — EBIT-cover -8.22x and EBITDA-cover -6.11x (EBITDA is negative), against thresholds of 1.5x and 3.0x. Operating margin -54.8% against net debt $292m.

STATUS CHANGE - hard gate now fires. Rev +24% but op margin -54.8% and EBITDA is negative against $431m debt / $139m cash, so both the coverage test and the net-debt/EBITDA test fail. +72% to consensus $5.72 does not survive a hard gate. Automotive semiconductor content into a weak auto cycle.

⚠ caution: thin data (quarterly revenue feed unreliable); cash runway ~1.4yr on a C$60-70m annual operating burn

DATA CORRECTION: the yfinance headline of revenue -95.3% is an artefact. The quarterly income statements show revenue RISING - C$35k (Q2 FY25), C$309k, C$672k, C$1.455m (Q1 FY26) - a genuine ramp in exchange volumes; the Q2 FY26 print of C$1,663 is a corrupted datapoint, not a collapse, so G is scored on the ramp and not on the bad field. Against that: operating loss runs C$13-20m a quarter (approximately C$60-70m/yr) on C$95.4m of cash, i.e. only about 1.4 years of runway - H 46 and the caution gate. D 47 gives real credit for the driver: a commodity-futures venue benefits from exactly the energy volatility this regime is generating. Consensus targets look stale (+311%). Donatien-Pick, currently Stopped.

New this run - XIT holding. Trades below book (P/B 0.92) with net cash C$352m = 20% of the market cap and positive FCF, which is the entire bull case. Against that: revenue growth has collapsed to +5.8% from 20%+, GAAP op margin is -1.1%, Rule of 40 is approximately 6, and consensus is Hold. D 39 - SMB retail and hospitality POS is levered straight to Cons Disc SU/SU/SU. Lands below the 45 line - No Interest, and per the roster-lane bloat guard it is shown this run but not carried forward.

⛔ hard: debt service impaired on BOTH bases — EBIT-cover -41.98x and EBITDA-cover -13.19x (EBITDA negative), against 1.5x and 3.0x. Net debt $1.58bn, revenue -30.5%.

Hard gate retained and now clearly deserved. Revenue is -30.5%, operating margin -165%, net debt $1.58bn (D/E 235%) against negative EBITDA - the coverage and leverage tests both fail. D 36 is the honest macro read: bitcoin mining is a power-price business, and an energy-shock regime with Brent above $100 attacks the single largest input cost. Now classified Financial Services (bitcoin treasury) rather than Technology - flagged for re-sectoring.

Scored off RHM.DE: rev +68.8%, fwd EPS EUR53.68 vs 26.08 trailing, PEG 0.35, ROE 25.7%, net debt/EBITDA ~1.3x; halved from its 52w high yet +65% to a EUR1,670 target - purest NATO-rearmament driver, D 90.

P/E 12.0 / fwd 10.1 with a 7.1% FCF yield, FCF conv 91%, ROE 27.8%, FMP A-, net debt/EBITDA 2.3x; ~87% US-government revenue takes the defense tailwind at the cheapest multiple in the sleeve.

FCF GBP2.94bn = 139% of net income, ROE 18.6%, net debt/EBITDA 2.1x, fwd P/E 19.8; ~95% defense and 80% of its 52w high - the steadiest European prime.

Net debt/EBITDA 0.66x, FCF yield ~9.2%, fwd P/E 18.1 on EPS recovering EUR7.26 -> 12.46; ~65% defence/security with avionics the commercial drag, +31% to target.

Op margin 19.4%, ROE 19.7%, FCF conv 102%, net debt/EBITDA 0.84x - the cleanest balance sheet in the sleeve; naval nuclear propulsion + defense electronics give D 80, offsetting a rich 38.9x P/E.

⚠ caution: provider share-count/EV broken - WASO 5.86bn and EV $3.99tn both unusable

Reconciled shares x price myself: $1,947.1bn cap / $147.79 = ~13.18bn shares, so EV ~= 1,947 + 39.7 debt - 100.0 cash ~= $1.89tn (NOT the $3.99tn the provider reports, and the FMP WASO of 5.86bn is the known-stale field). Q2 rev $7.81bn (+92% H1 YoY), GM 55.3% up from 49.1%, op income -$143m = near breakeven, net cash ~$60bn - but ~78x annualised sales and 88x forward earnings, so V 14; D 82 on Starshield + launch monopoly.

Rev +10.5%, fwd P/E 16.1, FCF $5.56bn (88% conv), net debt/EBITDA 1.6x; ~96% defense so takes the XAR O/O/SO tailwind clean, +21% to $637.84 target.

FCF conv 98%, net debt/EBITDA 0.8x, best relative strength in the sleeve (88% of 52w high); D held to 72 as Gulfstream (~22%) is bizjet into XLY SU.

Rev +10.1%, EPS +60%, FCF conv 102%, effectively debt-free (cash $270m vs debt $267m); 100% defense electronics, +49% to target - held back only by a 30.5x P/E and Leonardo SpA's ~72% control.

Genuinely excellent operationally - rev +24.1%, op margin 28.5%, ROE 34.7%, net debt/EBITDA 1.4x - but 50x trailing / 36x forward and 10.2x sales, and D falls 78 -> 60 because roughly half of revenue is commercial-aero engine and fastener content facing $100+ Brent. Great business, wrong price: 71 -> 69.